REVIEW

The role of TBK1 in cancer pathogenesis and anticancer immunity

Austin P. Runde†, Ryan Mack†, Peter Breslin S.J.1,2 and Jiwang Zhang1,3*

Abstract
The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by pathogen-associated molecular patterns (PAMPs), inflammatory cytokines, and oncogenic kinases, including activated K-RAS/N-RAS mutants. TBK1 primarily mediates IRF3/7 activation and NF-κB signaling to regulate inflammatory cytokine production and the activation of innate immunity. TBK1 is also involved in the regulation of several other cellular activities, including autophagy, mitochondrial metabolism, and cellular proliferation. Although TBK1 mutations have not been reported in human cancers, aberrant TBK1 activation has been implicated in the oncogenesis of several types of cancer, including leukemia and solid tumors with KRAS-activating mutations. As such, TBK1 has been proposed to be a feasible target for pharmacological treatment of these types of cancer. Studies suggest that TBK1 inhibition suppresses cancer development not only by directly suppressing the proliferation and survival of cancer cells but also by activating antitumor T-cell immunity. Several small molecule inhibitors of TBK1 have been identified and interrogated. However, to this point, only momelotinib (MMB)/CYT387 has been evaluated as a cancer therapy in clinical trials, while amlexanox (AMX) has been evaluated clinically for treatment of type II diabetes, nonalcoholic fatty liver disease, and obesity. In this review, we summarize advances in research into TBK1 signaling pathways and regulation, as well as recent studies on TBK1 in cancer pathogenesis. We also discuss the potential molecular mechanisms of targeting TBK1 for cancer treatment. We hope that our effort can help to stimulate the development of novel strategies for targeting TBK1 signaling in future approaches to cancer therapy.

Keywords: Autophagy, Cancer pathogenesis, Immunity, Inflammation, Mitophagy, Oncogenesis, Proliferation, Survival, TBK1, TBK1 inhibitor

Key points

1. TBK1 is activated by PAMPs, inflammatory cytokines and oncogenic kinases.
2. TBK1 coordinates inflammation and metabolism by regulating downstream signaling pathways.
3. TBK1 regulates the proliferation and survival of malignant cells in many types of cancer.
4. TBK1 regulates antitumor immunity and inflammation by regulating cytokine production in dendritic cells and macrophages.
5. TBK1 is a potential molecular anticancer target.

Background
The TANK-binding kinase 1 (TBK1; also known as NF-κB-activating kinase/NAK and T2K) is a serine/threonine kinase which serves important roles in the regulation of many cellular processes, including innate immunity, inflammatory cytokine production, autophagy, mitochondrial metabolism, and cell survival/proliferation [1–11].
TBK1 can be activated by pathogen-associated molecular patterns (PAMPs; molecules displayed or released by invading bacteria/viruses), damage-associated molecular patterns (DAMPs; molecules displayed or released by damaged tissues), inflammatory cytokines, and oncogenic kinases (in the context of this review, “activated” regarding TBK1 indicates the induction of TBK1 kinase activity by a stimulus; “activated” regarding K-RAS/NRAS and N-RAS/NRAS specifically indicates the oncogenic activity of these mutated GTPases/proto-oncogenes) [12–18]. The biological activity of TBK1 was first recognized in innate defenses against pathogens for its role in regulating the production of Type I interferons (IFN), including IFN-α and IFN-β. Recent studies have demonstrated that TBK1 links the pathogen-stimulated processes of inflammation/immunity, metabolism, and proliferation involved in many human diseases, including inflammatory diseases, type II diabetes (T2D), obesity, neurodegenerative diseases, and some cancers [19–29]. Mutation-associated haploinsufficiency of the TBK1 gene has been implicated as a causal event in several types of inflammatory/neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease/tauopathies, childhood herpes simplex virus-1 encephalitis (HSE), progressive supranuclear palsy-like syndrome, and a singular case of Parkinsonian-pyramidal syndrome [20, 22, 27, 30–35]. Copy-number gains of the TBK1 gene have been associated with normal-tension glaucoma and a single case of exfoliation glaucoma, but TBK1 does not appear to be involved in the pathogenesis of high-tension glaucoma; available data additionally suggest TBK1 is not involved in the pathogenesis of juvenile-onset open-angle glaucoma, pigmentary glaucoma, nor steroid-induced glaucoma, but further studies are necessary to confirm this [36–38]. The role of TBK1 in the pathogenesis of inflammatory diseases, T2D, obesity, and neurodegenerative diseases has been discussed in several outstanding reports [1, 21, 26, 39, 40]. In this review, we focus on the role of TBK1 in cancer development, progression, and metastasis in both preclinical animal models and clinical studies using patient samples. We discuss the molecular mechanisms by which TBK1 is regulated in cancer cells and, specifically, the role of TBK1 in the proliferation, survival, and immune system evasion of cancer cells. We expect that this review will provide insightful information and rationales for targeting TBK1 in therapeutic approaches in the field of oncology.

**TBK1 protein structure, interacting partners, and post-translational modification**

**TBK1 protein structure**

The TBK1 protein consists of 729 amino acids (aa). It is conserved across eukaryotes, with human paralogs having been identified in zebrafish, mice, primates, and amphibians. Mouse and human TBK1 share at least 94% sequence homology [41]. TBK1 belongs to the non-canonical IKK family and displays 64% homology to IκB kinase ε (IKKe; also known as IKKε) at the amino acid level. It has four archetypal domains: an N-terminal kinase domain (KD; aa1-307), a ubiquitin-like domain (ULD; aa308-384), and two coiled-coil domains (CCD1; aa407-657 and CCD2; aa659-713) (Fig. 1). The kinase domain is critical for the phosphorylation of various substrates, including IRF3. The Lys38 and Asp135 residues within the kinase domain mediate binding to ATP and catalytic activity, respectively. Both Lys38 and Asp135, as well as Ser172 (a key phosphorylation site), are necessary for the kinase activity and functioning of TBK1 [20, 42–44]. The ULD domain regulates kinase activity by binding to the kinase domain via its hydrophobic patch at Leu352/Ile353 [45]. The ULD also interacts with TBK1 substrates, such as IRF3/7 [45]. TBK1 with ULD deleted or an L352A/I353A mutation is able to induce neither the transcription factors for IFN-β and RANTES (Regulated on Activation, Normal T cell Expressed and Secreted; CCL5) nor phosphorylation of IκBα [46]. The CCD1 is also called the scaffold dimerization domain (SDD), which harbors a leucine zipper domain (LZ; aa499-527) and a helix-loop-helix domain (HLH; aa591-632), both of which mediate dimerization [20]. The CCD2 at the C-terminus harbors an adaptor-binding motif which facilitates the interaction of TBK1 with adaptor proteins, such as TANK, NAK–associated protein (NAP1), TBKBP1 (TBK1-binding protein 1; also known as SINTBAD), or optineurin (OPTN) [20, 43, 47, 48]. These adaptors bind to TBK1 in a mutually exclusive manner, thereby determining the ensuing subcellular localization of TBK1 and consequent downstream signaling specificity [49].

**Interacting partners of TBK1**

Over 50 proteins have been identified as interacting with TBK1 thus far. These interacting proteins can be divided into 3 groups, based on their functions: 1) adaptor proteins for bridging TBK1 to upstream and/or downstream signaling complexes, including TRIF, MyD88, MAVs, TRAF3, TRAF5, TRAF6, TRAF2, TAPE, NEMO, TANK, TBKBP1/SINTBAD, NAP1, STING, IFIT3, RAB8b, DNA-PK, NDP52 and OPTN [44, 47, 49–57]; 2) post-translational regulators of TBK1, including ubiquitin (Ub) ligases (MIB1, NRD1, UbcH5c, RNF128, DTX4, YAP, TRIP, and members of the TRIM E3 ligase family), the EGLN1 prolyl hydroxylase, deubiquitinating enzymes (DUBs) (A2O, TAXIBP1, USP2b, USP38, and CYLD), kinases (SRC, IKKB, ULK1, GSK3β, DYRK2 and PCK8), phosphatases (PPM1B, PP4C, Cdc25A, SHP2 and SHIP) and histone deacetylases (HDACs) [58–67]; and 3) substrates that can be phosphorylated by TBK1 and/or
mediate TBK1 activity, including molecules involved in IRFs-IFN signaling (IRF3, IRF7, DDX3X, STAT3, STAT6, STING), NF-κB signaling (IKKα, IKKβ, NIK, RelA, cRel, IkBa, NFATc1, TANK, PELI1, ACT1, XIAP, and RIPK1), autophagy (OPTN, p62, CYLD, AMPKα1, RAB7, mLRRK2), proliferation (AKT, mTor, CEP170, NuMA, PLK, and Sec5), insulin signaling (IR; insulin receptor), and neuronal cell functioning (e.g. Ser214 on tau) [10, 15, 24, 27, 39, 42, 54, 57, 68–82] (Fig. 1). The binding sites of many of these partner proteins have been determined (Fig. 1). Generally, adaptor proteins bind to TBK1 at its CCD2 site, post-translational regulators bind to either the KD or CCD1/SDD, and downstream substrates bind to the ULD [45, 49, 83]. Future studies are needed to determine whether these binding partners directly bind to TBK1 or do so indirectly by binding polyubiquitin (poly-Ub) chains or other adaptor proteins.

Each unique upstream stimulus can induce the interaction between TBK1 and a stimulus-specific adaptor protein; as such, the subcellular localization of TBK1 is dependent on and differs according to each stimulus. For example, TANK is localized to the perinuclear region in a punctate-appearing pattern; the binding of TANK to TBK1 induces TBK1-IRF3 pathway activation and the production of IFNα and IFNβ. In contrast, TBK1 binds NAP1 or OPTN in autophagosomes, therein regulating autophagy [71]. Stimulator of interferon genes protein (STING) localizes within the endoplasmic reticulum, while TIR-domain-containing adapter-inducing interferon-β (TRIF, also known as TICAM1) and TBK1-associated protein in endolysosomes (TAPE) localize to endosomes; both are able to induce TBK1-IRF3/IRF7 signaling for type I IFN production [52, 53]. Mitochondrial proteins MAVS and IFIT3 (IFN-induced protein with tetratricopeptide repeats 3) [52, 53] and Golgi complex protein OPTN all promote selective autophagy of damaged mitochondria (i.e. mitophagy) [76]. Thus, subcellular localization of TBK1 is regulated by the selective binding of specific adaptor proteins, which regulate its activity and substrate specificity [82].

**Fig. 1** TBK1 protein structure and interaction partners. TBK1 has four archetypical domains: an N-terminal kinase domain (KD), an ubiquitin-like domain (ULD), and two coiled-coil domains (CCD1 and CCD2). The CCD1 domain is also referred to as a scaffold dimerization domain (SDD), which harbors a leucine zipper (LZ) and a helix-loop-helix domain (HLH, aa591-632). The interacting partner proteins of TBK1 are listed and their corresponding binding sites are depicted.
different types of stimuli, including viral RNA/DNA and bacterial LPS [16, 84–86, 90–94]. K30 and K401 poly-Ubn provides a platform for both adaptor protein (e.g. NEMO, TBKBP1/SINTBAD, NAP1, NDP52, and OPTN) and substrate (e.g. IRF3/7) binding, to propagate downstream signaling activity [95]. K63-linked poly-Ubn also promotes the interaction of the CCD2 domain with adaptor proteins. The TBK1 adaptor proteins TANK, NAP1, TBKBP1/SINTBAD, and OPTN all have distinct subcellular localizations. As these proteins complex with TBK1, they ultimately promote the consequent localization and sequestration of TBK1 in their respective cytosolic compartments. As such, TBK1 adaptor proteins can promote the formation of higher-order TBK1 oligomers, therein forming TBK1-adaptor protein signaling machinery in distinct, functionally-specific subcellular locations [43, 44, 83, 96]. This results in regional activation of TBK1 by transautophosphorylation on Ser172 within the kinase activation loop (aa160–175), an essential step for kinase activation [43, 44, 97, 98].

TBK1 has also been observed to undergo SUMOylation on its C-terminal K694 [88]. Such SUMOylation sterically excludes some adaptor proteins, like TANK, allowing TBK1 to interact with other protein complexes, thereby enabling its innate immunity-activating function.

Although Ser172 phosphorylation of TBK1 is primarily mediated by autophosphorylation, it can also be phosphorylated by Ikkβ, suggesting crosstalk with the Ikk protein family, and by ULK1 as part of the inflammatory response to antigen detection [39, 99]. In addition, autophosphorylation of Ser172 is regulated by phosphorylation of other residues by several kinases. For example, after being recruited to the TNF-receptor associated factor 3 (TRAF3) complex, GSK3β complexes with TBK1 to mediate activation of TBK1 via autophosphorylation on Ser172 independent of GSK3β kinase activity [75, 97]. Furthermore, in K-RAS-activated lung epithelial cells, PKCθ is activated by mutant K-RAS, which phosphorylates TBK1 on Ser710 in a TBKBP1- and CARD10-dependent manner, triggering the autophosphorylation and activation of TBK1 [100]. Src binds to adaptor proteins (such as TRIF, MAVS, and STING) and phosphorylates TBK1 on Tyr179, which is crucial for the TBK1-mediated activation of IRF3[101]. During RNA virus infections, MAVS-mediated TBK1/Ikkε activation requires both TRAF-mediated TBK1 autophosphorylation and TRAFs-NEMO-Ikkβ-mediated TBK1 phosphorylation [86].
Since TBK1 activation is primarily mediated by autophosphorylation and K63-linked poly-Ub, aberrant TBK1 activation is prevented by both phosphatases and DUBs. Several phosphatases, including PPM1B, PPM1A, PP4C, Cdc25A, SHP2, and SHIP1, have been reported to suppress TBK1 activity via phosphatase action on Ser172 of TBK1 [43, 62–64, 66, 97, 98, 102]. In addition, several DUBs, including A20, TAX1BP1, USP2b, and CYLD, have been shown to remove K63-linked poly-Ub chains from TBK1, thereby inhibiting the TBK1-IRF3 signaling pathway [61, 103–105]. Moreover, TBK1 can also be negatively regulated via phosphorylation. For example, Lck/Hck/Fgr-mediated phosphorylation on Y394/354 of TBK1 disrupts its dimerization, and thus its activation, during the innate antiviral response [106]. Dyrk2-mediated phosphorylation of Ser527 triggers DTx4 or Traip-mediated K48-linked poly-Ub on K670, leading to proteasomal degradation [91, 107–110]. Interestingly, this K670 residue can be modified through K33-linked poly-Ub by a currently unidentified Ub ligase [108]. USP38 specifically cleaves K33-linked poly-Ub chains from TBK1 at K670, thereby enabling subsequent K48-linked Ub by DTx4 and TRIP on the K670 residue. USP38 also inhibits type I IFN signaling by promoting the NLRP4 signalosome-mediated degradation of TBK1 [108]. In addition, the interaction of TRAF3IP3 with TRAF3 and TBK1 induces DTx4-mediated K48-linked Ub of TBK1 on its K372 residue, therein promoting degradation of TBK1 [107]. As well, Nedd4 catalyzes the K27-linked poly-Ub of TBK1 on its K344 residue, which serves as a recognition signal for cargo receptor NDP52-mediated autophagic degradation [8]. Siglec1 suppresses the antiviral innate immune response by inducing TBK1 degradation, wherein Siglec1 induces the TRIM27 Ub ligase to mediate K48-linked Ub of TBK1 on K251 and K372 [111]. In response to infection with an RNA virus, TBK1 is ubiquitinated (Ub) on residues K69, K154, and K372; residues K69 and K154 are critical for innate antiviral responses and IFN production [112]. TRAF-interacting protein (TRIP) promotes K48-linked Ub and consequent proteasomal degradation of TBK1, thus inhibiting TLR3/4- and RIG-I-induced IFN-β signaling [110]. SOCS3 catalyzes K48-linked poly-Ub of TBK1 on residues K341 and K344 and promotes subsequent TBK1 degradation [113]. Furthermore, Yap/TAZ interacts with TBK1 and blocks Mib2-mediated K63-linked poly-Ub of TBK1 and its adaptor proteins, thus inhibiting the association of TBK1 with IRF3, MAVS, and STING [114–116].

TBK1 activity is also positively and negatively regulated by acetylation [59]. Nine lysine residues on TBK1 can be modified by acetylation: K30, K154, K236, K241, K251, K607, K646, K691, and K692, as indicated by mass spectrometry. K241 acetylation during the early stage of viral infection enhances the recruitment of IRF3 to TBK1. Deacetylation of K241 and K692 is critical for the kinase activity and dimerization of TBK1, respectively [59]. The acetyltransferases which mediate TBK1 acetylation are not yet known. However, several HDACs have been reported to either positively or negatively regulate TLR-mediated and virus-stimulated innate immune responses. HDAC3 directly deacetylates TBK1 on K241 and K692, resulting in the activation of TBK1. Interestingly, HDAC3 activity is promoted when TBK1 is phosphorylated on Ser424. HDAC9 deacetylates TBK1 on K241 for activation of antiviral innate immunity, which is enhanced by the methyltransferase DNMT3A [58]. HDAC4 interacts with the kinase domain of TBK1/IKKε, blocking the phosphorylation of IRF3 in order to suppress IRF3-mediated IFNβ expression [117].

A recent study demonstrated that TBK1 undergoes a downregulatory S-nitrosylation on its Cys423 residue [118]. The study suggested that Cys423 S-nitrosylation occurs due to reactive nitrogen species produced during viral infection. As such, it is suggested that GSNOR prevents S-nitrosylation of TBK1, thereby preserving the immune-activating functions of TBK1 amid viral infection.

TBK1 levels are also regulated by autophagy, such that inhibition of autophagy can result in aberrant activation of TBK1, suggesting that the activity of TBK1 is subject to negative regulation by autophagy, at least in K-RAS-activated murine pancreatic cells [9].

**TBK1-mediated signaling pathways**

*Upstream signaling stimulates TBK1 activation*

TBK1 can be activated by viral and bacterial infection, inflammatory cytokines, and oncoproteins (such as activated K-RAS) [119]. During pathogen infection, pattern-recognition receptors (PRR) allow for the cellular recognition of conserved molecular signatures of microbial PAMPs, which activate TBK1. Based on protein domain homology, PRRs have been divided into several families, including: Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), cytosolic DNA sensors (CDS), NOD-like receptors (NLRs), and absent in melanoma-2 (AIM2)-like receptors (ALRs) [12–14] Fig. 3.

Human TLRs consist of 10 family members which can be divided into 2 subgroups, cell surface TLRs (including TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) and endosomal TLRs (including TLR3, TLR7, TLR8, and TLR9) [120]. Different TLRs recognize distinct types of PAMPs; cell surface TLRs mainly recognize the membrane components of pathogens, while endosomal TLRs primarily recognize cytosolic nucleic acids. For example,
TLR2 along with either TLR1 or TLR6 recognize lipoproteins, peptidoglycans, lipoteichoic acids, zymosan, mannan, and tGPI-mucin; TLR3 detects viral dsRNA and poly(IC); TLR4 recognizes bacterial lipopolysaccharide (LPS); TLR5 recognizes bacterial flagellin; TLR7/8 detect ssRNA; TLR9 detects unmethylated CpG DNA molecules; and TLR10 senses influenza A virus (IAV) infection and cooperates with TLR2 to recognize the PAMPs of Listeria. After binding to their corresponding PAMP(s), most TLRs stimulate the activation of myeloid differentiation factor 88 (MyD88)-IRAK1/IRAK4-TRAF6, NF-κB, and TBK1 signaling, while only TLR3 and TLR4 stimulate TRIF-TRAF3-TBK1 signaling in endosomes [121].

There exist 3 RLRs: RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) [122]. RLRs detect foreign RNA in the cytoplasm. Activated RLRs induce STING in the endoplasmic reticulum, which then translocates to the Golgi and recruits TBK1 [76, 83, 87, 136, 137]. Among these 3 CDSs, dsDNA stimulates a conformational change in cGAS that allows ATP and GTP to enter the catalytic pocket, leading to the synthesis of cGAMP, a potent activator of the STING-TBK1 axis. During intracellular bacterial infection, autophagy receptor NDP52 recognizes Ub-coated bacteria and recruits the adaptor proteins NAP1 and TBKBP1 to activate TBK1 [138]. TBK1 then promotes autophagy and the invading microbial pathogens can be selectively eliminated (xenophagy) [4, 5, 7]. Furthermore, TBK1 can also
be activated by inflammatory cytokines including APRIL, BAFF, IL-1, and IL-17, as well as by activated K-RAS in cancer cells, as will be discussed in later sections [16–18, 78, 139–141].

**Downstream substrates and signaling pathways of TBK1**

TBK1 is a key mediator of immune response/inflammation, autophagy, proliferation/growth, survival, insulin signaling and metabolism. Mass spectrometric analysis of TBK1 knockdown in lung cancer cells identified 385 proteins with altered phosphorylation [142]. Over 50 substrates have been identified experimentally thus far. These can be divided into several groups based on their functions and the signaling pathways they impact: immune response/inflammation (IRF3, IRF7, DDX3X, IKKa, IKKβ, NIK, RelA, cRel, IkBa, ACT1, Pel1, STAT1, STAT3, STAT6, XIAP), autophagy (OPTN, LC3C, CYLD, AMPKα1, Rab7, GABARAP-L2, p62/SQSTM1, mLRK2, Stx17, PINK1/Parkin), cellular proliferation and mitosis (Akt, mTOR, Raptor, mTORC1, P70S6, GSK3α, CEP170, NuMA, PLK, metadherin, Sec5, Cdc20, and Cdh1), insulin and metabolic signaling (insulin receptor, PDE3B and ACSL), and apoptosis/necroptosis ( RIPK1) [6, 42, 54, 57, 70, 73, 142–145]. As previously mentioned, several adaptor proteins such as STING, TANK, TRAF2, TRIF, MAVS, and MITA are also substrates for TBK1 (Fig. 3 and Table 1). While the roles of TBK1 in insulin signaling, metabolism, and neurodegenerative disease have been discussed in several excellent reviews [21, 82], we will focus on the roles of TBK1 in the regulation of inflammation/immunity, cellular proliferation/survival, and autophagy due to the involvement of these processes in oncogenesis and disease progression.

**TBK1 is a critical mediator of immunity and inflammation**

Upon pathogen detection, TBK1 is induced by upstream adaptor proteins and receptors. TBK1 is an early effector of the innate immune system, with its activation occurring very shortly after pathogen detection. The primary function of TBK1 is to induce production of type I IFN, such as IFN-α/β, in innate immune cells; TBK1 does so largely via its association with and phosphorylation of IRF3 and IRF7 [175–177]. Activated TBK1 directly phosphorylates IRF3/7 on multiple Ser and Thr residues. Phosphorylation of Ser386 and Ser396 on IRF3 is believed to be critical for IRF3 activation [146–148], while phosphorylation of Ser 477 and 479 of IRF7 is believed to be necessary for IRF7 activation [178]. The phosphorylated IRFs form homo- and/or hetero-dimers, translocate into the nucleus, and bind IFN-stimulated response elements (ISRE) in the promoters of target genes, such as *IFNB* and *RANTES* [134]. IRF dimers subsequently regulate target gene expression by recruiting p300 and CBP co-activators [179], and by cooperating with several other transcription factors, such as NF-κB, PU.1, and SMADs [180]. In addition, the transcriptional activity of IRF3 is regulated by PTEN, by DNA-PK and by DDX3X (a DEAD-box helicase family member). PTEN promotes activation of the innate immune system via phosphatase action on Ser97 of IRF3, an inhibitory residue, thereby

**Table 1** The substrates of TBK1 and their corresponding signaling pathways

| Pathways                  | Substrates                                                                 |
|---------------------------|----------------------------------------------------------------------------|
| IRF3/7-IFN pathway        | IRF3 at Ser339/386/396 [146–151]                                           |
|                           | IRF7 at Ser471/472 [152, 153]                                               |
|                           | DDX3X at Thr542, Ser543 [42]                                                |
|                           | STAT3 at Ser754, 727 [72, 154]                                               |
|                           | STAT6 at Ser407, Tyr641 [155]                                                |
| NF-κB signaling           | PEL1 at Ser76/293, Thr288 [156]                                              |
|                           | IKKβ at Ser177/181 [41]                                                     |
|                           | NIK at Ser62 [78]                                                           |
|                           | XIAP at Ser430 [157]                                                        |
|                           | CYLD at Ser418 [158]                                                        |
|                           | RIPK1 at Thr189 [74]                                                        |
| Mitotic regulators        | p65 NF-κB (RelA) at Ser536 [70, 159, 160]                                   |
|                           | cRel at Ser479/602 [70]                                                     |
|                           | IkBa at Ser36 [41, 161]                                                     |
|                           | Metadherin at Ser568 [142]                                                  |
|                           | ACT1/TRAF3IP2 at Ser162/220/233/311 [162]                                   |
| AKT-mTor signaling       | AKT1 at Thr195/308, Ser378/473/476 [2]                                      |
|                           | Raptor at Ser877 [15]                                                       |
|                           | mTOR at Ser2159/2481 [68, 164]                                               |
|                           | S6K at T421/542/424 [165]                                                    |
|                           | Sec5 [69]                                                                  |
|                           | GSK3α at Ser21 [44]                                                         |
|                           | SRC at Tyr179 [101]                                                         |
| Autophagy pathway         | AMPKα1 at Ser459/476 [39], Thr172                                           |
|                           | LC3C at Ser93/96 [71]                                                       |
|                           | GABARAP-L2 at Ser87/88 [71]                                                  |
|                           | p62/SQSTM1 on Ser403/366 [4]                                                 |
|                           | mLRK2 at Ser910/935/995 [166]                                                |
|                           | OPTN at Ser177/473/513 [54, 167]                                             |
|                           | STX17 at Ser202 [73]                                                        |
|                           | RAB7A at Ser72 [54]                                                         |
| Adaptor proteins          | STING at Ser324/358/366 [134, 168, 169]                                      |
|                           | TRIF at Ser210/212, Thr214 [169]                                             |
|                           | MAVS at Ser442 [169]                                                        |
|                           | MVB12b at Ser222 [170]                                                      |
|                           | TANK at Ser49/126/178/208/228/257 [99]                                       |
|                           | TRAF2 at Ser11 [171]                                                        |
| Insulin/glucose signaling | IR at Ser994 [25]                                                           |
|                           | PDE3B at Ser 318 [172]                                                      |
|                           | Exo84 Ser8 [173]                                                            |
| Others                    | Tau at Ser214/324/356 [27]                                                   |
|                           | HTT at Ser13/16 [28]                                                        |
|                           | ERa at Ser305 [174]                                                         |
|                           | YAP1 at Thr110/114, Ser128/131                                               |
|                           | HDAC3 at Ser424 [59]                                                        |
TBK1 mediates cytosolic DNA-induced/STING-dependent on cell- and signal-specific contexts [119]. TBK1-mediated activation of NF-κB seems highly and eventual liver failure [161]. Subsequent investigation determined that the embryonic lethality observed in Tbk1−/− C57BL/6 mice is embryonic-lethal by embryonic day 14.5. This complex. In TBK1-deficient cells, merely physiological Thr189, thus mediating retention of RIPK1 in the survival multiple cell lines, TBK1 directly phosphorylates STAT3 on Ser754, thereby restricting cytosolic DNA-induced/STING-dependent activation of both the IRF3 and NF-κB pathways [83, 185]. NF-κB cooperates with IRF3 to induce production of proinflammatory cytokines, including type I IFN and IFN-β, which induces proliferation by regulating survival/proliferative genes, including BCL-xl, XIAP, Cyclin D1, and RelB [184]. TBK1-mediated activation of NF-κB seems highly dependent on cell- and signal-specific contexts [119]. TBK1 mediates cytosolic DNA-induced/STING-dependent activation of both the IRF3 and NF-κB pathways [83, 185]. NF-κB cooperates with IRF3 to induce production of proinflammatory cytokines, including type I IFN [186]. The activation of both the IRF3 and NF-κB pathways mediates an immune defense against both tumors and viruses [83, 185]. Understanding these functions of TBK1, we can understand why patients with heterozygous loss-of-function Tbk1 mutations are susceptible to herpes simplex infection, as observed in HSE patients [35].

In addition to the IRF and NF-κB pathways, TBK1 can also activate STAT3, and STAT6, thereby promoting an inflammation-induced innate immune response. In multiple cell lines, TBK1 directly phosphorylates STAT3 on Ser754, thereby restricting cytosolic DNA-induced STAT3 transcriptional activity [72]. In dendritic cells (DCs), TBK1 binds to and phosphorylates STAT3 on Ser720, thereby suppressing both the type I IFN response and STAT1 activation [154]. Regarding STAT6, TBK1 phosphorylates STAT6 on Ser407, leading to the dimerization and nuclear translocation of STAT6, and consequent production of STAT6-responsive genes, including the chemokines CCL2/20/26 [155]. Thus, TBK1 acts as a central player in the innate immune system by regulating inflammation during the response to pathogens.

Interestingly, germline knockout of Tbk1 in C57BL/6 mice is embryonic-lethal by embryonic day 14.5. This is due to unrestrained apoptosis and necroptosis in murine hepatocytes, resulting in severe inflammation and eventual liver failure [161]. Subsequent investigation determined that the embryonic lethality observed in Tbk1−/− C57BL/6 mice was a result of TNFα-stimulated hyperactivation of RIPK1. Mechanistically, TBK1 attenuates the activation of RIPK1 by phosphorylating it on Thr189, thus mediating retention of RIPK1 in the survival complex. In TBK1-deficient cells, merely physiological levels of TNFα can stimulate the release of RIPK1 from the survival complex; as such, the uninhibited RIPK1 subsequently forms a death complex in the cytosol and induces both caspase 8-mediated apoptosis and RIPK3-MLKL-mediated necroptosis [74, 145]. Either TNFα deletion or RIPK1 kinase inactivation can prevent the early embryonic death of Tbk1−/− C57BL/6 mice. In addition, germline Tbk1−/− mice with a 129S5 background are able to survive due to the lack of the Tnfrsf1b gene [187]. As cells that die from necroptosis are highly immunogenic/inflammatory, mice with Tbk1 loss-of-function mutations display pathological, whole-body inflammation compared to wild-type mice [188]. Thus, TBK1 has been shown to play a critical role in the prevention of inflammation by suppressing TNFα-RIPK1-mediated cell death. Consistent with these studies in animal models, recently, homozygous point mutations of TBK1 (including W619X, Y212D, and R440X) were detected in 4 patients with an unidentified chronic, systemic autoimmune syndrome [189]. All these mutations are loss-of-function mutations. The W619X and R440X mutations induce nonsense-mediated mRNA decay and cause markedly reduced Tbk1 mRNA levels, while the Y212D mutation attenuates IRF3-IFN signaling activity. Although Tbk1-null cells display compromised TLR3-TRIF and cGAS-STING signaling, RLR-MAVS signaling is maintained, suggesting that the loss of TBK1 is partially compensated by IKKε. Consequently, all four patients presented with normal antiviral immune function. The autoimmune symptoms which developed in these patients might be associated with over-activation of TNFα signaling because they could be ameliorated by anti-TNFα therapy [189]. Such a clinical observation is consistent with the laboratory findings in animal models that TBK1 restrains TNF-induced RIPK1-MLKL activation [74, 145].

**TBK1 is a key regulator of selective autophagy and xenophagy**

Autophagy is a homeostatic cellular process by which cellular components, such as organelles or protein aggregates, are degraded in a lysosome-dependent manner [190]. It is an important process by which cellular nutrients are recycled, damaged/unneeded organelles are resolved, and the health of the cell is maintained [190]. Following the inhibition of mTOR or the activation of AMPK, and subsequent formation of the unc-51-like kinase 1 (ULK1) complex (ULK1/2, ATG13, FIP200/RB1CC1 and ATG101), autophagy is initiated via the nucleation of the phagophore upon budding from the surface of the endoplasmic reticulum [21, 191–193]. The ULK1 complex recruits and phosphorylates the transmembrane protein ATG9 and the class
III phosphatidylinositol 3-kinase (PI3KC3) complex (PI3KC3/VPS34, PIK3R4/VPS15, beclin-1, ATG14, as well as associated factors AMBRA1 and NRB2), which in turn promotes autophagosome biogenesis [190]. The ATG16L1 complex of lipidation cascade enzymes (ATG3, ATG7, ATG12-ATG5-ATG16L1) induces the conjugation of Atg8/LC3/GABARAPs (autophagy modifiers) to phosphatidyethanolamine by facilitating ATG4-mediated lipidation of LC3-I to form LC3-II and anchor LC3-II to the growing phagophore. LC3-II supports both expansion and closure of the autophagosome (double-membraned vesicle), allowing it to properly engulf its targets. Autophagosomes are studded with RAB7, which facilitates fusion with lysosomes to form autolysosomes for the degradation of the substrate/cargo.

Autophagy can be classified as either nonselective/bulk or selective types. Nonselective autophagy is normally induced by starvation, which degrades cellular substrates indiscriminately to refill the nutrients [191, 194, 195]. Selective autophagic processes include mitophagy, ER-phagy, pexophagy, aggrephagy and xenophagy, which mediate the degradation of damaged mitochondria, endoplasmic reticula, peroxisomes, protein aggregates, and intracellular pathogens, respectively [195, 196]. Mitophagy, ER-phagy and aggrephagy are critical for controlling the quality of mitochondria/metabolism, ER/protein synthesis and protein folding [197–199], whereas xenophagy is a process by which intracellular pathogens are eliminated [190]. During selective autophagy, Ubd cargoes are recognized by autophagic receptors including p62/SQSTM1, OPTN, NDP52/CALCOCO2, TAX1BP1, NBR1 (neighbor of BRCA-1), and NIX (BNIP3L). These receptors contain an LC3-interacting region (LIR) and an Ub-binding domain (UBZ), which facilitate autophagosome fusion through LC3-LIR binding and selective binding to Ubd cargo via the UBZ (Fig. 4).

During autophagy, TBK1 is activated by AMPK-mediated phosphorylation [200]. In addition, Ub-marked cargoes recruit TBK1 to sites of damaged cargoes or pathogens and induce TBK1 activation locally by autophosphorylation on Ser172 [7, 55, 201–203]. Phosphatidylinerine-specific phospholipase PLA1A mediates full activation of TBK1 through recruitment to mitochondria and interaction with MAVS [89, 204]. TBK1 regulates autophagy by phosphorylating autophagic modifiers and receptors, thereby increasing their binding affinities. For example, TBK1 phosphorylates the autophagic receptors OPTN, NDP52, TAX1BP1 and p62 on their Ub-binding and LIR domains to facilitate the binding of autophagic receptors to Ubd cargoes and LC3 [3, 11, 31, 57, 77, 138, 167, 190, 205–208]. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria [54]. TBK1 phosphorylates syntaxin 17 on Ser202 to control the initiation of autophagy [73]. In addition, TBK1 phosphorylates RAB7A on Ser72, which promotes the recruitment of ATG9 vesicles to damaged mitochondria [54]. TBK1 also phosphorylates LC3C on Ser93/96 and GABARAP-L2 on Ser87/88, preventing premature
cleavage of LC3s from nascent autophagosomes by ATG4 [71]. Thus, TBK1 plays a critical role in the maintenance of normal mitochondrial metabolism by promoting mitophagy of damaged mitochondria [3, 22].

During viral infection, TRIM23 mediates TBK1-dimerization and activation, which is required for early autophagic induction and p62 phosphorylation for viral clearance [34, 56]. In response to an invasive bacterial infection, TBK1 phosphorylates NDP52 and contributes to autophagic maturation and the elimination of mycobacteria [4]. Furthermore, TBK1 regulates the integrity of pathogen-containing vacuoles and prevents bacterial egress into the cytosol, where hyperproliferation can occur [209]. Therefore, TBK1 is required for combating pathogens by linking inflammation/cytokine production and xenophagy. Because several adaptors and substrates of the TBK1 pathway such as STING and IRF3 are degraded during autophagy [5, 210], the TBK1-driven autophagic feedback loop is also responsible for the attenuation of cGAS-STING-IRF3-IFN signaling [5, 210]. TBK1 mediates crosstalk between energy sensing and inflammatory signaling pathways [39].

**TBK1 is a critical mediator of cell proliferation**

TBK1 promotes cellular survival and proliferation through activation of the AKT-mTOR, STAT3, and NF-kB signaling pathways. TBK1 also regulates mitosis by phosphorylating key regulators, including PLK1, CEP170, NuMA, Cdc20, and Cdh1a [80, 142, 163]. Evidence suggests that TBK1 is activated during mitosis and is necessary for cell division [6]. In proliferating cells, phosphorylation of TBK1 on Ser172 coincides with phosphorylation of histone H3, a mitotic indicator, and the kinetics of TBK1 activation are correlated to PLK1 phosphorylation on Thr210; PLK1 is an enzyme that regulates chromosomal segregation, spindle assembly checkpoint, and maintenance of genomic integrity [142, 211]. Hyper-activation of PLK1 causes excessive phosphorylation of BUBR1, CEP192, and INCENP, thereby resulting in mitotic dysregulation. Ser172 phosphorylation on TBK1 leads to TBK1 localization to centrosomes and mitotic spindles, where it regulates microtubule dynamics and mitosis. TBK1 phosphorylates the centrosome-associated CEP170 on multiple sites, resulting in the binding of CEP170 to the Kif2b microtubule depolymerase [80]. TBK1 also phosphorylates the NuMA mitotic apparatus protein on multiple sites, which is necessary for the latter to bind the microtubule motor dynein.

Cdc20 and Cdh1 are cofactors for the anaphase-promoting complex/cyclosome (APC/C) which regulates the exit from metaphase, segregation of sister chromatids and entry into anaphase [212]. In lung and breast cancer cell lines, TBK1 phosphorylates Cdc20 on Ser134 and Cdh1 on Thr20, Ser39, Ser42, Ser58, Ser131, and Ser151 [163]. Inhibition of TBK1 leads to centrosome amplification, mitotic defects, growth arrest, and apoptosis. Interestingly, OPTN and the PINK1/Parkin pathway recruit TBK1 to mitochondria during mitophagy, which results in a G2/M block due to the loss of TBK1 on centrosomes and mitotic spindles. Thus, TBK1 provides an intriguing connection between innate immune signaling, autophagy/mitophagy, and the cell cycle [6, 213].

**Studies of Tbk1 knockout mice**

Germline Tbk1 knockout (Tbk1−/−) mice of a C57BL/6 background die of liver failure [161], whereas Tbk1−/− mice of 129S5 background (Tbk1Δ/Δ) are viable but highly sensitive to LPS-induced inflammation and display neurodegenerative phenotypes [24, 187]. Tissue-specific Tbk1 knockout mice have provided useful models to study the roles of Tbk1 in somatic cells. So far, tissue-specific deletion of Tbk1 has been studied in several types of immune cells, including CD4+ T cells [2], CD11c+ dendritic cells (DCs), CD19+ B cells, and lysosome 2/M (Lyz2)-expressing myeloid cells [214], as well as villin-expressing intestinal epithelial cells, albumin-expressing hepatocytes, nestin-expressing neurons, and adiponecin-expressing adipocytes (Table 2).

In CD4+ T cells, Tbk1 acts as a negative regulator of Akt signaling; Tbk1 phosphorylates Akt on Ser378, thereby inducing degradation of Akt. Loss of Tbk1 perpetuates aberrant activation of the AKT-Foxo1/AKT-mTORC1-S6K1 pathways, resulting in both enhanced T-cell activation and impaired T-cell migration [2]. T-cell-specific deletion of Tbk1 leads to increased sensitivity of T cells to activating stimuli, an increased fraction of the T-cell population being in either the T effector (Teff) or T memory (Tmem) state at the expense of the T naïve (Tn) population, and impaired exit of Tn from lymph nodes [2].

Tbk1 in myeloid cells primarily restricts inflammatory responses. Myeloid-specific Tbk1 knockout mice (My-Tbk1−/−) spontaneously developed adipose hypertrophy and metabolic disorders in old age due to the increased M1 macrophage infiltration and proinflammatory cytokine production (such as IL-6, TNF-α, and IL-1) in adipose tissue. Such mice are hypersensitive to high-fat diet (HFD)-induced hepatic inflammation, insulin resistance and non-alcohol-induced steatohepatitis (NAISH)-like fatty liver disease, as well as to dextran sulfate sodium (DSS)-induced experimental colitis. Mechanistic studies suggest that Tbk1 negatively regulates TLR-stimulated MAPK and IKK/NF-kB signaling and proinflammatory cytokine production. The disease phenotypes observed in My-Tbk1−/− mice can be largely prevented by either genetic or pharmacologic
| Genotype                        | Knockout strategy                                                                 | Phenotype                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Germline Tbk1^{−/−} [161]      | Homologous-recombination targeting/knockout of exons 1-2 of Tbk1                 | Embryonic-lethal at E14.5 due to liver failure, resulting from aberrant death of hepatocytes induced by TNFα-RIPK1 signaling.                                                                                                                                                                                                                                                   |
| Germline Tbk1^{Δ/Δ} [24, 187]  | Prm1-Cre-mediated excision of Tbk1 exon 2 to yield global truncation of Tbk1, mice of 129S5 background (lack of the Tnfrsf1b gene) to circumvent embryonic-lethal phenotype of Tbk1 deficiency [187] | Exhibit mononuclear and granulomatous cell infiltrates in multiple organs and inflammatory cell infiltrates in their skin; hypersensitive to LPS stimulation [187]. Reduced weight gain and pancreatic abnormalities amid high-fat diet; increased insulin sensitivity due to absence of Tbk1-mediated inhibition of insulin receptor signaling [24]. |
| Tbk1^{fl/fl}, neuron-specific [207] | Nestin-Cre                                                                        | ALS/FTD symptoms as demonstrated by cognitive and locomotor deficits. Resulting from impaired autophagy in motor neuron-like cells                                                                                                                                                                                                                                                |
| Tbk1^{fl/fl}, adipocyte-specific [39] | Adiponectin-Cre                                                                  | Attenuates HFD-induced obesity by increasing energy expenditure, as TBK1 directly inhibits AMPK to suppress respiration and increase energy storage; increased inflammation and decreased insulin sensitivity because Tbk1 represses NF-κB activity.                                                                                                                                                     |
| Tbk1^{fl/fl}, myeloid cell-specific [215–218] | Lyz2-Cre                                                                         | In IAV infection model, knockout mice display dampened immune response to IAV and improved survival. This is due to reduced recruitment of CD64^{+}SiglecF^{-}Ly6C^{hi} inflammatory macrophages, and reduced expression of inflammatory cytokines in the bronchoalveolar lavage fluid, and reduced expression of both IRF- and NF-κB-target genes in the lung [217]. In ALS model, knockout mice develop accelerated ALS due to the increased inflammatory cell infiltration, which induces motor deficits and axonal damage [216]. Eight month-old mice displayed adipocytic hypertrophy, increased M1/decreased M2 macrophage infiltration, and increased pro–IL-1β protein level in eWAT. Four week-old mice fed HFD developed liver abnormalities consistent with NAISH. Mice also displayed insulin-glucose axis dysfunction and increased disease severity in a DSS-induced colitis model [215]. |
| Tbk1^{fl/fl}, T cell-specific [2] | Cd4-Cre                                                                           | Impaired T-cell migration (T_{eff} egress from draining lymph nodes) due to the enhanced activation of AKT-mTORC1 signaling axis. In a neuroinflammatory autoimmunity model, Tbk1 knockout in T cells represses the development of experimental autoimmune encephalomyelitis (EAE).                                                                                                                                 |
| Tbk1^{fl/fl}, dendritic cell-specific [154] | CD11c-Cre                                                                       | Upregulation of costimulatory molecules, increased T-cell-priming activity and upregulation of a subset of genes by IFNAR. Mice develop autoimmune symptoms and display enhanced antitumor immunity.                                                                                                                                                                                                                                             |
| Tbk1^{fl/fl}, B cell-specific [78] | Cd19-Cre                                                                          | Uncontrolled production of IgA and the development of IgA nephropathy-like disease; activation of the noncanonical NF-κB pathway in B cells.                                                                                                                                                                                                                                                                                     |
| Tbk1^{fl/fl}, intestinal epithelia-specific [219] | Villin-Cre                                                                      | Increased MT1 expression; increased number of Th17 cells in lamina propria; increased production of IL-1β by intestinal macrophages; increased number/size of intestinal neoplasms.                                                                                                                                                                                                                                                  |
| Tbk1^{fl/fl}, hepatocyte-specific [144] | Albumin-Cre                                                                      | Increased liver lipid due to reduced β-oxidation of acyl-CoA/acyl-CoAs fatty acids; fasting-state mitochondrial localization of ACSL1 is impeded.                                                                                                                                                                                                                                                                               |
inhibition of IL1 through IL-1R signaling, suggesting a critical role for Tbk1 in restricting TLR-stimulated inflammatory reactivation [215]. Another study reported that My-Tbk1−/− mice developed an abnormal inflammation of the small intestine in old age characterized by mucosal infiltration of inflammatory macrophages [216]. In an ALS model with mutant human SOD1G93A overexpression, My-Tbk1−/− mice developed an accelerated ALS-like phenotype compared to SOD1G93A Tbk1+/+ mice. This phenotypic expression consists of axonal destruction complicated by reduced integrity of myelin resulting from increased inflammatory cell infiltration [216]. However, in IAV infection model, My-Tbk1−/− mice experience both decreased inflammation and mortality in response to viral infection when compared with wild-type mice, despite no differences in viral load. Compared to wild-type mice, My-Tbk1−/− mice had fewer CD64+SiglecF−Ly6Chi inflammatory macrophages, as well as reduced expression of both IFR3 and NF-κB target genes in the lung tissue, suggesting that Tbk1 is required for IAV infection-induced recruitment of CD64+SiglecF−Ly6Chi inflammatory macrophages to the alveoli of the lung and inflammatory cytokine production [217]. These studies altogether point to context-specific roles for Tbk1 in different types of macrophages.

In CD11c+ B cells, Tbk1 negatively regulates the non-canonical NF-κB pathway by phosphorylating NIK on Ser862, thereby triggering NIK degradation [78]. Mice with B cell-specific Tbk1 deletion displayed an uncontrolled production of IgA and the development of human IgA nephropathy-like disease because Tbk1-NIK signaling modulates IgA class switching [78].

In CD11c+ DCs, Tbk1 suppresses the expression of IFNα-regulated genes and immunostimulatory molecules [154]. Mice with a DC-specific deletion of Tbk1 displayed more Tmem cells and IFNy+ T cells with reduced Tn cells in their spleens, suggesting Tbk1 in DCs restrains Tn-cell activation. Consistent with this notion, such mice developed autoimmune symptoms as they aged, yet displayed a remarkable ability to resist the neoplastic growth of xenografted melanoma, thymoma, and lymphoma [154]. The autoimmune and enhanced antitumor phenotypes seen in mice are associated with the elevated ratio of splenic Tmem/Tn Population.

In hepatocytes, Tbk1 mediates β-oxidation of acyl-CoAs/fatty acids via its interaction with ACSL1. Interestingly, this Tbk1-ACSL1 interaction only occurs when Tbk1 is inactive [144]. In the fasted state, Tbk1 complexes with ACSL1 in mitochondria to mediate β-oxidation; however, in the fed state, Tbk1 does not associate with ACSL1, allowing ACSL1 to translocate to the ER where it mediates the re-esterification and consequent storage of fatty acids. As such, hepatocyte-specific deletion of Tbk1 in mice results in fatty liver disease due to a lack of Tbk1-mediated sequestration of ACSL1 in mitochondria, thereby causing a defect in the β-oxidation of fatty acids.

In motor neurons, Tbk1 plays a critical role in the regulation of autophagy and, thus, of neuronal cell health [20]. Duan et al. demonstrated a mouse neuron-specific deletion of Tbk1 results in the accumulation of intracellular p62+ protein aggregates and neurofibrillary/tau tangles in neurons, such that the affected mice display ALS/FTD-like symptoms [207].

In adipocytes, Tbk1 controls energy metabolism and suppresses inflammation. Tbk1 expression is upregulated in adipocytes of HFD-fed mice, which suppresses AMPK-mediated lipid oxidation/mitochondrial biogenesis and NIK-mediated non-canonical NF-kB pathway. Mice with adipocyte-specific deletion of Tbk1 developed a T2D-like phenotype as demonstrated by increased insulin resistance/glucose intolerance and inflammation/macrophage infiltration of adipose tissues due to the activation of non-canonical NF-kB signaling. However, such mice are relatively resistant to HFD-induced obesity due to the elevated AMPK-mediated lipid oxidation and mitochondrial biogenesis [39, 220]. Interestingly, mice with whole body Tbk1 knockout maintain insulin sensitivity because Tbk1 is a negative regulator of the IR [24]. Such mice are protected from HFD-induced weight gain, inflammation, and diabetes. The distinct phenotype of adipocyte-specific Tbk1 knockout mice and whole body Tbk1 knockout mice suggests a critical role of Tbk1 in other cell types such as macrophages and that it might play an essential role in the regulation of insulin sensitivity and glucose tolerance.

Role of TBK1 in the pathogenesis of cancer

Emerging evidence suggests that TBK1 plays critical yet tissue-variable roles in the pathogenesis of cancer [23, 221]. While TBK1 mutations are not commonly reported in human cancers, increased TBK1 expression and/or aberrant TBK1 activity are reported in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, clear cell renal cell carcinoma (ccRCC), adult T-cell leukemia, melanoma, esophageal cancer, and breast cancer, among others [142, 221–223]. In these cancers, TBK1 activity is positively correlated with disease progression thus serving as an indicator of poor prognosis, specifically in those tumors harboring activated K-RAS/N-RAS, suggesting TBK1 functions as an oncoprotein at least in these cancer types [16, 79, 142, 165, 174, 224–226]. The tumorigenic activity of TBK1 has been verified in several cancer models, suggesting that TBK1
may be an attractive molecular target for antineoplastic drugs [17, 81, 100, 225]. TBK1 can promote cancer development and progression via several mechanisms, including: 1) stimulating both survival and proliferation signals in cancer cells (i.e. cell-autonomous mechanism); 2) mediating the production of tumorigenic, immunosuppressive cytokines (i.e. autocrine-like mechanism); and 3) suppressing anticancer functions of the immune system by both upregulating the expression of immune checkpoint ligands (e.g. PD-L1) and perpetuating the inflammatory, macrophage-laden tumor microenvironment (i.e. cell-nonautonomous mechanism) [9, 51, 100, 222]. In addition, TBK1 in immune cells (e.g. DCs and CD8+ T cells) might antagonize antitumor immunity, thus promoting tumor development [154]. However, TBK1 is downregulated in uterine corpus endometrial carcinoma and oligodendroglioma, where it may function as a tumor suppressor. Therefore, carefully studying the roles of TBK1 in different types of cancer will help to develop a rationale for targeting TBK1 as part of an anti-neoplastic therapeutic strategy.

**Molecular mechanisms by which TBK1 is upregulated and activated in cancer tissues**

As is the case in normal cells, TBK1 activation in cancer cells can be stimulated by PAMPs, DAMPs, and inflammatory cytokines. In addition, some oncogenic kinases and receptor tyrosine kinases (such as K-RAS/N-RAS and AXL) can also activate TBK1 in neoplastic cells [23].

K Ras is mutated in a wide array of human cancers, including: 1) stimulating cancer cell survival and proliferation by activating both the NF-κB and mTOR1 pathways [16, 68, 165]. Activation of NF-κB promotes the expression of anti-apoptotic Bcl-Xl while the activation of mTOR1 induces protein-synthetic pathways, both of which contribute to tumorigenesis [23]. TBK1 activates NF-κB signaling by phosphorylating critical regulators of the NF-κB pathway, including IκBa, RelA, and IKKβ [1, 39, 70, 233]. In addition, TBK1 has been shown to complex with multiple AKT-mTORC1-regulatory elements, including AKT, Raptor, RagD, and S6K [165]. TBK1 can activate mTORC1 signaling directly (by phosphorylating mTOR on Ser2481), or indirectly (by phosphorylating AKT on Tyr308 and Ser473, or by mTORC2-mediated phosphorylation of AKT on Ser473). AKT activates mTORC1 signaling via the canonical pathway [79, 229]. In addition, TBK1 can directly promote S6K C-terminal Thr421/Ser424 phosphorylation [1, 39, 223]. It was known that KRAS/NRAS-activating mutations promote the activation of both MEK-ERK and AKT-mTOR signaling in tumor cells [16, 18, 223]. The TK1-dependent mTOR signaling activation in K-RAS/N-RAS-activated tumor cells suggests that TK1-mTOR and MEK-ERK constitute parallel survival and proliferative signaling pathways in such tumor cells [18, 223, 234]. However, despite the biological plausibility of combination TK1/MEK inhibition as an anticancer therapy, resistance to this regimen develops rapidly in mouse models of K Ras G12D, lkb1 null and K Ras G12D, Trp53 null lung cancers due to the epigenetic-mediated upregulation of IGF1 and YAP1 [235]. Addition of the BET inhibitor JQ1 can inhibit both IGF1 and YAP1 signals, thereby resensitizing these tumors to TK1/MEK inhibition [235]. Combination inhibition of TBK1, MEK, and BET (using MMB, trametinib, and JQ1, respectively) results in prolonged antitumor activity in both models.
In K-RAS-activated PDA, TBK1 functions downstream of AXL and supports both growth and metastasis of PDA cells by apparently reprogramming epithelial cell fate. In the KRasLSL-G12D/+ Cdkn2aLox/LoxPtf1aCre/+ PDA mouse model, Tbk1 deletion in the malignant cells resulted in reduced tumor load and reduced metastatic behavior, indicating that Tbk1 activity contributes directly to the aggressive properties of pancreatic cancers. Tbk1-null cancer cells are more differentiated and less invasive than Tbk1-intact cancer cells in mice [17]. In primary melanoma patient samples, TBK1 is hyperactive in a subtype of BRAF/MEK inhibitor-resistant tumor cells; this subtype of melanoma displays hyperactive TLR/innate immune system signaling. TBK1 activation in such tumor cells is primarily stimulated by TGFβ, which promotes the survival of tumor cells by activating AKT and YAP signaling pathways. TBK1 protects YAP/TAZ from proteasomal degradation. Consequently, such melanoma cells are vulnerable to treatment with a TBK1 inhibitor [115, 225, 236].

However, TBK1 inhibits mTOR signaling in bone marrow-disseminated prostate cancers (PCa) [10, 237]. This mTOR-related inhibitory role for TBK1 was also observed in other types of somatic cells and T-cells in mice [8, 168]. TBK1 plays such a role by phosphorylating Raptor on Ser877 probably in a subcellular localization-dependent fashion [10, 15]. Bone metastatic lesions are associated with a poor prognosis and are detected in approximately 70% of patients with breast cancer or PCa and 15-30% of patients with carcinomas of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney [238]. Using the PCa PC3 cell line and a transplantation mouse model, Taichman’s laboratory demonstrated that PC3 cells compete with hematopoietic stem cells (HSC) for bone marrow niche occupancy [239]. Within HSC niches, PCa cells are resistant to conventional treatments because they are maintained in a cell cycle-quiescent state (G0) and display a cancer stem cell-like phenotype. TBK1 expression in PCa cells is induced by stromal cell attachment, which inhibits mTOR-p70S6K signaling and contributes to their dormant/stem-like phenotype. TBK1 knockdown induces the activation of mTOR-p70S6K signaling and increases the sensitivity of cancer cells in bone marrow niches to docetaxel treatment as demonstrated by a xenograft model [237].

In addition to NF-κB and mTOR, TBK1 can also promote cancer development and progression through other pathways. Loss of copy number of chromosome...
3p is strongly correlated with the development of both inherited/familial and sporadic clear-cell renal cell carcinoma (ccRCC). The VHL gene, which encodes the pVHL tumor suppressor, resides on chromosome 3p and is frequently deleted in ccRCC tumors [240, 241]. As such, it is believed that loss of pVHL functionality is a critical driver of ccRCC. Hu et al. demonstrated that phosphorylation of TBK1, and thus TBK1 kinase activity, is increased in ccRCC tumor tissues and is required for the survival of VHLnull ccRCC cells [81]. Mechanistically, it was found that the EGLN1 prolyl hydroxylase mediates hydroxylation on Pro48 of TBK1, thereby enabling the pVHL-associated E3 Ub ligase machinery to complex with TBK1. Upon associating with the Pro48-hydroxylated TBK1, pVHL recruits PPM1B to dephosphorylate TBK1, thereby blocking the kinase activity of TBK1. In VHLnull ccRCC tumor cells, loss of VHL copy number results in hyperactivation of TBK1, which leads to increased autophagy, due to TBK1-mediated phosphorylation of p62/SQSTM1 on Ser366. Interestingly, VHLnull ccRCC cells rely on TBK1-p62-induced autophagy for their survival. As a consequence, TBK1 inhibition leads to synthetic lethality in VHLnull ccRCC cells [81].

In breast cancers, TBK1 expression was significantly higher in most breast tumor tissues compared to matched adjacent normal tissues as demonstrated by immunohistochemical staining of 171 breast cancer samples. Mechanistically, the N-terminal fragment of TBK1 (aa1-510) interacts with the DNA binding domain of estrogen receptor α (ERα) and phosphorylates it on Ser305, which consequently perpetuates the transcriptional activity of ERα. Increased expression of TBK1 is positively correlated with ERα and cyclin D1 expression, as well as phosphorylation of ERα on Ser305. TBK1 inhibition sensitizes breast cancer cells to tamoxifen-induced cell death [174].

In acute myeloid leukemia, higher levels of TBK1 and IKKε expression were detected in leukemic cells compared to CD34+ HSPCs isolated from healthy donors. Genetic ablation of either TBK1 or IKKε induces apoptosis in AML cells that express high levels of MYC, suggesting that both kinases are required for the survival of MYChigh leukemic cells. Pharmacologic inhibition of TBK1/IKKε suppresses AML development and progression in a xenograft model as demonstrated by a reduction in overall leukemic burden [231]. Mechanistic studies suggested that TBK1 and IKKε phosphorylate YB1 on Ser102, therein promoting the YB1-mediated expression of MYC. Compared to normal HSPCs, AML cells appear to rely more heavily upon TBK1/IKKε; this TBK1/IKKε addiction plausibly provides a selective therapeutic opportunity for AML patients via pharmacologic inhibition of TBK1/IKKε [18, 231].

**TBK1 promotes the proliferation and survival of cancer cells by promoting autocrine cytokine signaling**

In diffuse large B-cell lymphoma (DLBCL), TBK1 mRNA levels negatively correlate with prognosis in both germinal center and non-germinal center types of DLBCL [242]. In DLBCL cells, TBK1 mediates the activation of canonical NF-κB signaling via phosphorylation of p65/RelA on Ser536, which promotes the production of IL-10, CCL3, and CCL4; these cytokines promote tumorogenesis by stimulating STAT3 activation. As such, TBK1 is predicted to mediate the activation of NF-κB/STAT3 in DLBCL, thereby promoting disease progression. As demonstrated in cell line and patient sample studies, treatment with the TBK1/IKKε inhibitor DMX3433 attenuated canonical NF-κB signaling and decreased DLBCL cell viability [224]. Furthermore, TBK1 is required for the survival of HTLV-1 (Human T-Lymphotropic Virus type 1)-transformed T lymphocytes through the maintenance of STAT3 activity. Thus, inhibition of TBK1/IKKε induces apoptosis in HTLV-1+ T lymphoma cells [226]. The study of several human cancer cell lines by Korherr et al. revealed that TBK1-IRF3 signaling can be activated in response to hypoxia. TBK1 mediates the production of RANTES, IL-8, and other proangiogenic factors in these cells. These factors stimulate tumor angiogenesis by promoting the proliferation of endothelial cells, suggesting that TBK1 may function as an angiogenic effector [243].

**TBK1 promotes tumor development through an immunosuppressive tumor environment**

The tumorigenic activities of TBK1 are not only mediated by intrinsic mechanisms as described above, but also by attenuating the antitumor functions of the immune system, which occurs through upregulation of immune checkpoint ligands and the maintenance of an immunosuppressive molecular signature in the tumor microenvironment [100].

In several types of murine cancer models, TBK1 mediates the production of immunosuppressive cytokines and chemokines which induce the expression of the immune checkpoint ligand programmed cell death-ligand 1 (PD-L1) and/or the accumulation of immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs). For example, in a mouse model with Kras-activated lung cancers, Tbk1 induces local immunosuppression by facilitating EGF-induced PD-L1 expression on tumor cells. Deletion of Tbk1 in tumor epithelial cells reduces the number of both PD-L1 expressing cells and MDSCs
in the tumor microenvironment, the reduction being associated with a local increase in CD8+ T-cells [100]. In HPV+ cervical cancer cells, high interferon-inducible 16 (IFI-16) expression is associated with increased PD-L1. Using a xenograft model, Cai et al. demonstrated that IFI-16 promotes cervical cancer progression by upregulating PD-L1 in the tumor environment via the STING-TBK1-NF-kB pathway [51]. Similarly, in hepatocellular carcinoma (HCC) patients, TBK1 expression was found to be higher in tumor tissues compared to adjacent normal tissues [222]. High TBK1 expression in tumor tissues is associated with reduced tumor-infiltrating CD8+ T-cells and increased immunosuppressive markers; thus, upregulation of TBK1 serves as a negative prognostic indicator for HCC patients. Interestingly, the TBK1 antagonist GSK8612 inhibits HCC cell growth only in immunocompetent animal models due to its effects on CD8+ T-cell infiltration [222]. In the mouse model of cerulein-induced pancreatitis/K-RasG12D PDA, TBK1 in the tumor cells promotes neutrophil recruitment and T-cell infiltration by stimulating the production of cytokines, such as CCL5 and IL-6, and the upregulation of PD-L1 [9]. This was supported further by another study that demonstrated that the loss of Tbk1 significantly enhanced the antineoplastic effect of PD-1 blockade in melanomas and in other models of malignancy [244].

The protumor and antitumor activities of TBK1 in immune cells

Within immune cells such as DCs, cytotoxic T-cells, and macrophages, the role of TBK1 signaling in the anti-pathogen immune-response has been well-documented; however, the role of TBK1 signaling in anticancer immunity has only been assessed in DCs [17, 245]. DC-specific Tbk1 knockout mice developed autoimmune symptoms such as aberrant T-cell activation, splenomegaly, and lymphadenopathy, as well as lymphocytic tissue infiltrates. Using a B16-OVA melanoma cell implantation model, Xiao et al. demonstrated that such mice display an enhanced ability to resist neoplastic growth coupled with an increased responsiveness to PD-1/PD-L1 blockade [154]. Mechanistically, TBK1 activates STAT3 signaling in DCs, thereby attenuating IFNAR-STAT1 signaling and suppressing both the expression of costimulatory molecules and T cell-priming activity [154]. Nevertheless, the tumor immune roles of TBK1 in myeloid cells, T cells and B cells have not been evaluated in any cancer models [2, 78, 217]. Thus, the role(s) of TBK1 in immune cells with respect to the pathogenesis of cancer are largely unknown.

Tumor suppressive activity in APC-mutated intestinal tumors

TBK1 mRNA has been observed to be increased in some human colorectal cancers. Such upregulation can, perhaps surprisingly, serve as a favorable prognostic indicator in rectal adenocarcinomas [219, 222]. These studies suggest that, in contrast to its tumorigenic role observed in most cancer types, TBK1 appears to possess tumor-suppressive activity in at least some colorectal cancers. Such anti-tumor activity of TBK1 has recently been discovered in a mouse model of Apc-mutated intestinal tumors [219]. ApcMin/+ develop intestinal polyps by 5 months of age. Yang et al. recently demonstrated that a villin+ intestinal epithelium-specific deletion of Tbk1 enhanced intestinal tumorigenesis, as shown by significant increases in the number and size of intestinal polyps [219]. Further study suggested that Tbk1 in intestinal epithelial cells (IECs) suppresses NF-kB-mediated metallothionein 1 (MT1) production. Deletion of Tbk1 in IECs leads to MT1 production within the lamina propria. MT1 stimulates macrophages to produce IL-1β, which then promotes the expansion of Th17 cells. Aberrant expanded Th17 cells promote tumor IEC growth by producing Th17 cytokines [219].

TBK1 as a chemotherapeutic target for cancer treatment

Owing to the scope of its involvement and function in processes both within and outside the cancer cells, TBK1 has gained considerable interest as a possible drug target for cancer treatment. Many TBK1 inhibitors have been developed (Table 3), most of them being dual inhibitors of both TBK1 and IKKe. The antineoplastic effects of several TBK1 inhibitors have been assessed in vitro (Table 4) and evaluated in animal models (Table 5). Most of these TBK1 inhibitors have displayed anticancer activities in animal models and shown synergism with other anticaner therapies, including temozolomide (TMZ) and MEK/BET inhibition. Despite abundant in vivo data from preclinical investigations supporting the use of AMX as anticancer therapy, the only TBK1 inhibitor to enter clinical trials thus far has been MMB. This is largely due to the effect of MMB on IKKe, Tbk1 and JAK1/2.

Oral AMX has been evaluated in the clinical setting, but only for the treatment of metabolic disorders, specifically NAFLD, obesity, and T2D (Table 3) [40, 262, 265, 266, 277, 278]. Oral administration of AMX in doses of 25-50 mg TID in a 12-week trial produced a statistically significant decrease in both serum HbA1c and fructosamine levels. However, these improvements in metabolic parameters seem to be lost upon discontinuation of the drug. Some patients in both trials displayed rashes diagnosed as perivascular inflammation, a pathology similar to the inflammatory skin lesions seen in Tbk1Δ/Δ mice, suggesting an on-target side effect of TBK1 inhibition [187, 279]. While these studies demonstrated that oral AMX is safe, well-tolerated, and effective in ameliorating metabolic abnormalities, the efficacy of AMX as an
antineoplastic agent is unknown but warrants clinical investigation [247, 280].

MMB has been evaluated for the treatment of metastatic PDA, EGFR- or K-RAS-activated NSCLC (Table 3) [18, 261–267]; however, oral MMB at doses of 100-300 mg QID did not show any clinically meaningful benefit, neither as monotherapy nor in combination with other drugs. The pharmacodynamics studies indicated that even with average maximal plasma concentrations of ~300 ng/mL, TBK1 was not inhibited to any therapeutically-significant extent [18, 262, 264–267]. One study with mouse RAW 264.7 gamma NO(−) macrophages suggested that MMB concentrations between 500 nM and 1 μM are required to block the kinase activity of TBK1 [18]. MMB has also been evaluated for the treatment of myelofibrosis, a disease associated with mutations and aberrant activation JAK2 signaling. In three phase 3 trials (two SIMPLIFY trials and one MOMENTUM trial),

### Table 3 Summary of current TBK1 inhibitors

| Compounds                  | Targets                     | Reference | Clinical Trial                          |
|----------------------------|-----------------------------|-----------|-----------------------------------------|
| Amlexanox (AMX)            | TBK1/IKKε                   | [40, 246–252] | NCT01842282, NCT01975935               |
| AZ13102909 (AZ909)         | TBK1                        | [223]     |                                         |
| BAY-985                    | TBK1/IKKε                   | [253]     |                                         |
| BX79S                      | TBK1/IKKε, Aurora B, NUAK1, PDK1 | [254–256] |                                         |
| Compound I                 | TBK1/IKKε                   | [244]     |                                         |
| Compound II                | TBK1/IKKε                   | [229, 257] |                                         |
| DMX-14                     | TBK1/IKKε                   | [258]     |                                         |
| GSK8612                    | TBK1                        | [259]     |                                         |
| MDK10496                   | TBK1/IKKε                   | [260]     |                                         |
| MMB/CYT387/GS-0387         | TBK1/IKKε, A20/1, ALK2, JAK1/2 | [231, 261–267] | NCT02101201, NCT02206763, NCT02258607, NCT04173494/MOMENTUM, NCT01969838/SIMPLIFY1, NCT02101268 |
| MBB/CYT387/GS-0387         | TBK1/IKKε                   | [231, 261–267] | NCT02101201, NCT02206763, NCT02258607, NCT04173494/MOMENTUM, NCT01969838/SIMPLIFY1, NCT02101268 |
| MBI-0485520                | TBK1/IKKε                   | [268]     |                                         |
| MRT67307                   | TBK1/IKKε, ULK1/2           | [99]      |                                         |
| MRT68601                   | TBK1                        | [255]     |                                         |
| UNC6587/Cereblon-TBK1 PROTAC | TBK1/IKKε, Aurora A, GSK3β, Aurora A, PDK1 | [269]     |                                         |
| 200A                       | TBK1/IKKε                   | [270]     |                                         |
| 3αipVHL-TBK1 PROTAC        | TBK1                        | [271]     |                                         |

### Table 4 Summary of the in vitro antineoplastic activities of TBK1 inhibitors

| Molecule                  | Findings                                                                                                                                                                                                 | Reference                                      |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| AMX                       | Inhibits growth of ALL cells (RS4;11 and SEM), displays synergism with TMZ in glioblastoma cells (U87MG) and patient samples, and attenuates the metastatic phenotype in prostate cancer cells (PC3 and DU145). | [247, 272, 273]                                |
| Compound II               | Can induce apoptosis in lung cancer cells (HCC44, H1993, H2073, and H441), including H358 (K-RASG12C) and SK-LU-1 (K-RASG12D).                                                                        | [229]                                         |
| AZ909                     | Significantly attenuates the growth of N-RAS-activated melanoma cells (WM1366, SBcl2, and WM1346), displays synergism with MEK inhibitors.                                                                 | [223]                                         |
| MMB/CYT387/GS-0387        | Decreases viability of AML cells (OCI-AML5, MOLM13, MOLM14, and KASUMI-1).                                                                                                                               | [15]                                          |
| UNC6587/Cereblon-TBK1 PROTAC | Selectively slows the growth of VHL−/− ccRCC cells (UMRC6) while leaving VHL+/+/restored UMRC6 cells unaffected.                                                                                   | [80]                                          |
MMB displayed significant and promising treatment effects as demonstrated by reduced total symptom score and spleen volume as well as increased transfusion independence of patients for at least 12 weeks [263, 264, 281]. However, such treatment effects with MMB are primarily ascribable to the inhibition of JAK1/2 and ACVR1 signaling rather than inhibition of TBK1 signaling. It is also important to mention that MMB is metabolized differently across different mammalian groups, mainly undergoing morpholine ring oxidation in humans and amide hydrolysis in dogs/rats, thus yields different predominant metabolites between dogs/rats and humans [267]; the most abundant metabolite of MMB in humans, M21, is pharmacologically-active against JAK1/2 and ACVR1, whereas the most abundant MMB metabolite in dogs/rats, M19, is not. This finding is acknowledged to emphasize the reality that in vivo models, even dogs and large rodents, do not always translate directly to humans. As such, variations in drug metabolism between test and target species must be determined in any medicinal chemistry endeavor.

**Concluding remarks**

Many diverse studies have demonstrated that TBK1 plays a role in not only innate immunity and metabolism, but also in cancer development and progression. In most cancer types, TBK1 functions oncogenically, serving to promote tumorigenesis through both cell-intrinsic and cell-extrinsic mechanisms. Thus, blocking the action of TBK1 in most cancer cells is expected to attenuate the invasive/malignant phenotype. However, owing to the critical role of TBK1 in normal immune physiology/activation, the inhibition of TBK1 could impair antitumor immunity. Interestingly, the genetic inhibition of Tbk1 in DCs enhances antitumor immunity and arrests tumor development [154]. The roles of TBK1 in tumor immunity in other immune cells, including T and B cells as well as monocytes/macrophages, have not been sufficiently evaluated. While systemic inhibition of TBK1 augments antitumor immunity in most cancer types tested, particularly with concomitant immune checkpoint blockade, detailed analyses of the role of TBK1 in immune, tumor, and tumor microenvironment/stromal cells will be necessary to determine the advisability of targeting TBK1 as an antineoplastic therapeutic approach.

Cancer stem cells are unique types of cancer cell that are responsible for disease initiation, progression, and relapse [282, 283]. Compared to bulk tumor cells, cancer stem cells are relatively resistant to conventional therapies, likely due to their modulated metabolism. In examining its established involvement in mitophagy and mitochondrial metabolism, we hypothesize that TBK1 may contribute to the initiation and/or maintenance of the cancer stem cell phenotype [6, 54, 284]. As such, elevated TBK1 expression is associated with a poor prognosis in many cancer types. Future studies should evaluate the role of TBK1 in cancer stem cells and chemoresistance with the goal of determining whether pharmacologic inhibition of TBK1 can sensitize cancer stem cells to chemotherapy as a means of preventing disease relapse.

Much of the current literature suggests TBK1 inhibition could be an effective way to decrease cancer cell viability and invasiveness, across a remarkable range of cancer types, excluding those arising from villin+ intestinal epithelium [219]. Yet, it is still not entirely clear how cells/tissue types vary in their sensitivity to TBK1 inhibition. With respect to mutational status, some studies indicate that cancer cells harboring KRAS-activating mutations are vulnerable to K-RAS-TBK1 synthetic lethality, specifically when combined with ERK-MAPK inhibitors [9, 16, 18]. However, such effect is temporally due to BET-mediated drug-resistance. Thus, the addition of a BET inhibitor to the combination regimen of TBK1 and MEK inhibitors might prevent drug resistance and lead to prolonged antitumor activity. In addition, ccRCC cells harboring VHL deletions are inherently more sensitive to TBK1 inhibition, as the

| Compounds | Findings | References |
|-----------|----------|------------|
| AMX | Antitumor efficacy in mouse models of melanoma, glioblastoma, pro-B-cell leukemia, prostate cancer, and K-RAS-activated/CTLA4 blockade-resistant lung cancer. AMX and TMZ given in combination display synergism in human glioma cells in xenografts. | [100, 246, 249, 250, 252, 274] |
| Compound I | Antitumor capabilities when combined with PD-L1 blockade in mouse models of colorectal carcinoma. | [244, 270] |
| GSK8612 | Inhibits HCC development in animal models by attenuating the production of immunosuppressive cytokines, consequently allowing enhanced infiltration of CD8+ T cells into the tumor. | [222] |
| MMB | Affords increased survival and decreased spleen size in mouse models of ovarian carcinoma and AML, respectively, and displays synergism with trametinib in suppressing PDA growth in animals. | [231, 275, 276] |
| 200A | Anticancer activity in mouse models of squamous cell carcinoma. | [244, 270] |
loss of VHL appears to cause cells to become addicted to TBK1 to perpetuate tumorigenic autophagy [60]. Detailed analyses of the roles of TBK1 with respect to both cancer type and mutational status will be required to best inform the investigation of TBK1 inhibitors in the treatment of cancer. Of clinical relevance, data from the villin+ intestinal epithelium-specific knockout of Tbk1 suggest that the use of TBK1 inhibitors would be contraindicated in at least some patients with gastrointestinal carcinomas [219].

Finally, despite the significant antitumor effects of TBK1 inhibition demonstrated by in vitro culture systems and animal modeling, clinical benefit from the use of TBK1 inhibitors as cancer therapy was not observed with MMB and has yet to be investigated with AMX and others. Thus far, only MMB—an inhibitor of TBK1, IKKe, JAK1/2, and ACVR1/ALK2—has been evaluated in clinical trials. In multiple clinical trials, it was demonstrated that MBB failed to provide any appreciable benefit to metastatic patients, likely because it failed to adequately inhibit TBK1. Thus, the potency (e.g. IC_{50}) and selectivity (e.g. TBK1-selective versus TBK1/IKKe dual) should be considered when choosing which TBK1 inhibitors to pursue in clinical trials for cancer therapy. As well, perhaps existing but ineffective TBK1 inhibitors (e.g. MMB) can be optimized with medicinal chemistry research before being disregarded entirely. Most TBK1 inhibitors also inhibit IKKe. Inhibition of both TBK1 and IKKe might provide better antineoplastic efficacy since both kinases have been implicated in oncogenesis. Given their high degree of sequence homology, inhibition of either TBK1 or IKKe alone may lead to compensatory hyperactivation of the untargeted congener, thereby circumventing the drug’s inhibitory effect. Although, as TBK1 and IKKe may be non-redundant in some cases, further evaluation is needed to determine if and when, specifically, TBK1- or IKKe-selective inhibitors would be preferred versus TBK1/IKKe dual inhibitors. It is clear that additional, more detailed studies are required to elucidate the distinct roles of both TBK1 and IKKe across cancer types and mutational statuses, specifically within immune cell physiology.

Abbreviations

ACSL1: Acyl-CoA synthetase long-chain family member 1; AIM2: Absent in melanoma-2; ALRs: AIM2-like receptors; AMBRA1: Activating molecule in beclin-1-regulated autophagy; AMX: Amlexanox; ASD: Murine adipocytokine (Adiponectin)-specific deletion of Tbk1; AZ209: AZ13102909; CCD: Colleddomain; ccrCC: Clear-cell renal cell carcinoma; CD5: Cytosolic DNA sensors; DAI: DNA-dependent activator of IRFs, also known as DLM-1 or Z-DNA binding protein 1 (ZBP1); DAMPs: Damage-associated molecular patterns; DSS: Dextran sulfate sodium; DUBs: deubiquitinating enzymes/ deubiquitinases; eWAT: Epididymal white adipose tissue; IkB: Inhibitor of nuclear factor-κB; IAV: Influenza A virus; IFN: Interferon; IFI16: Interferon-inducible-16; IFIT3: IFN-induced protein with tetratricopeptide repeats 3; IKK: IkB kinase; IR: Insulin receptor; HFD: High-fat diet; HSE: Childhood herpes simplex virus-1 encephalitis; HTLV-1: Human T-lymphotropic virus type 1; IEI: Inborn error(s) of immunity; KD: Kinase domain; Lyz2: Lysozyme 2/Lysozyme M/LysM; LZ: Leucine zipper; MAVS: Mitochondrial antiviral signaling adaptor, also known as IPS-1, VISA, or Cardif; MDA-5: Melanoma differentiation-associated gene 5; MMB: Momelotinib, CYT387, GS-0387; MyD88: Myeloid Differentiation factor 88; NAFLD: Nonalcoholic fatty liver disease; NASHi: Non-alcohol-induced steatohepatitis; NAK: NF-κB-activating kinase (see also: TBK1); NAP1: NAK-associated protein, NBR1: Neighbor of BRCA1 gene 1; NDP52: Nuclear dot protein 52 kDa; NLRs: NOD-like receptors; NRFB2: Nuclear receptor-binding factor 2, NSCLC: Non-small cell lung cancer; OPTN: Optineurin; PAMPs: Pathogen-associated molecular patterns; PDA: Pancreatic ductal adenocarcinoma; PDE3B: Phosphodiesterase 3B; PK3C3/VPS34: Phosphatidylinositol 3-kinase catalytic subunit type 3; PI3RM/VPS15: Phosphoinositide 3 kinase regulatory subunit 4; PLK1: Polo-like kinase 1; Poly-Ub: Polyubiquitin; Poly-Ubn: Polyubiquitination; PRR: Pattern-recognition receptor; RIG-I: Retinoic acid-inducible gene 1; RLRs: RIG-I-like receptors; SINBAD: Similar to NAP1 TBK1 adaptor (synonymous with TBKBP1); SSD: Scaffold dimerization domain; T2D: Type II diabetes; TAPE: TBK1-associated protein in endosomes; TANK: TRAF family member-associated NFKB activator (HGNC Symbol); TANKBP1: TAX1BP1; Tax1 binding protein 1; TBK1: TANK-binding kinase 1; TBKBP1: TBK1-binding protein 1 (synonymous with SINBAD); TRAFs: Toll-like receptors; TMZ: Temozolomide; TRIF: TNF receptor-associated factor; TRIF: TIR-domain-containing adapter-inducing interferon-β, also known as TICAM1; TRIP: TRAF-interacting protein; Ub: Ubiquitin; Ubn: Ubiquitination; ULD: Ubiquitin-like domain.

Acknowledgments

We thank Dr Rolf Brekken (UT Southwestern) for providing a synthesis scheme for Compound II.

Authors’ contributions

APR and RM drafted the first version of this review; P8 and JZ did the final editing. All authors contributed to the writing of this manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by: [1] the National Heart, Lung, and Blood Institute of the NIH (R01 HL133560-01/Jiwang Zhang); [2] the National Cancer Institute of the NIH (R01 CA223194-01/Jiwang Zhang); [3] Loyola Program Development funds (Jiwang Zhang); [4] the National Institute of Allergy and Infectious Diseases of the NIH (Experimental Immunology Training Grant: 2T32 AI007508-21/Ryan Mack).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Cancer Biology, Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL 60153, USA. 2 Departments of Molecular/Cellular Physiology and Biology, Loyola University Medical Center and Loyola University Chicago, Chicago, IL 60660, USA. 3 Departments of Pathology and Radiation Oncology, Loyola University Medical Center, Maywood, IL 60153, USA.

Page 19 of 25
3. Matsumoto G, et al. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation. Hum Mol Genet. 2015;24(15):4429–42.

4. Pilli M, et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity. 2012;37(2):23–34.

5. Prabakaran T, et al. Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. EMBO J. 2018;37(8):e97858.

6. Sarraf SA, et al. PINK1/Parkin influences cell cycle by sequestering TBK1 at damaged mitochondria, inhibiting mitosis. Cell Rep. 2019;29(1):225–235 e5.

7. Thurston TL, et al. Recruitment of TBK1 to cytosol-invading Salmonella induces WRAP2-dependent antibacterial autophagy. EMBO J. 2016;35(16):1779–82.

8. Xie W, et al. Selective autophagy controls the stability of TBK1 via NEDD4 to balance host defense. Cell Death Differ. 2021;29(1):40–53.

9. Yang S, et al. Autophagy inhibition Dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol Res. 2016;4(6):520–30.

10. Hasan M, et al. Chronic innate immune activation of TBK1 suppresses mTORC1 activity and dysregulates cellular metabolism. Proc Natl Acad Sci U S A. 2017;114(4):746–51.

11. Vargas JNS, et al. Spatiotemporal control of ULK1 activation by NDPS2 and TBK1 during selective autophagy. Mol Cell. 2019;74(2):347–362.e6.

12. Kugelberg E. Pattern recognition receptors: curbing gut inflammation. Trends Mol Med. 2016;22(6):511–27.

13. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Nat Rev Immunol. 2014;14(9):583.

14. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291.

15. Antonia RJ, et al. TBK1 limits mTORC1 by promoting phosphorylation of raptor Ser877. Sci Rep. 2019;9(1):13470.

16. Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.

17. Cruz VH, et al. Ax1-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. JCI Insight. 2019;4(9):e126117.

18. Zhu Z, et al. Inhibition of KRAS-driven tumorigenesis by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452–65.

19. Durand JK, Zhang Q, Baldwin AS. Roles for the IKK-related kinases TBK1 and IKBK epsilon in Cancer. Cells. 2018;7(9):139.

20. Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017;10(1):5.

21. Ahmad L, et al. Human TBK1: a gatekeeper of Neuroinflammation. Trends Mol Med. 2016;22(6):511–27.

22. Harding O, et al. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc Natl Acad Sci U S A. 2021;118(24):e202503118.

23. Alam M, Hasan GM, Hassan MI. A review on the role of TANK-binding kinase 1 signaling in cancer. Int J Biol Macromol. 2021;183:2364–75.

24. Cruz VH, et al. Loss of TBK1 kinase activity protects mice from diet-induced metabolic dysfunction. Mol Metab. 2018;16:139–49.

25. Munoza MC, et al. TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J Endocrinol. 2009;202(2):185–97.

26. Shin CH, Choi DS. Essential roles for the non-canonical IkappaB kinases in linking inflammation to Cancer, Obesity, and Diabetes. Cells. 2019;8(2):178.

27. Abreha MH, et al. TBK1 interacts with tau and enhances neurodegeneration in tauopathy. J Biol Chem. 2021;296:100760.

28. Hegde RN, et al. TBK1 phosphorylates mutant Huntington and suppresses its aggregation and toxicity in Huntington's disease models. EMBO J. 2020;39(7):e104671.

29. Rehman R, et al. Acute TBK1/IKKe inhibition enhances the generation of disease-associated microglia-like phenotype upon cortical stab-wound injury. Front Aging Neurosci. 2021;13:684171.

30. Santos-Garcia D, et al. First case of Parkinsonian-pyramidal syndrome associated with a TBK1 mutation. Mov Disord. 2021;36(2):523–5.

31. Foster AD, et al. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Mol Cell Neurosci. 2020;108:103539.

32. Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631–6.

33. Wilke C, et al. Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol Aging. 2018;62:244.e9–244.e13.

34. Ahmad L, et al. Human TANK-binding kinase 1 is required for early autophagy induction upon herpes simplex virus 1 infection. J Allergy Clin Immunol. 2019;143(2):765–769 e7.

35. Herman M, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med. 2012;209(9):1567–82.

36. Fingert JH, et al. Copy number variations on chromosome 1q24 in patients with normal tension glaucoma. Hum Mol Genet. 2011;20(12):2482–94.

37. Fingert JH, et al. Tank-Binding Kinase 1. Trans Am Ophthalmol Soc. 2016;114:76.

38. Ritch R, et al. TBK1 gene duplication and normal-tension glaucoma. JAMA Ophthalmol. 2014;132(5):544–8.

39. Zhao P, et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell. 2018;172(4):731–743 e12.

40. Oral EA, et al. Inhibition of IKKe and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab. 2017;26(1):157–170. e7.

41. Tojima Y, et al. NAK is an IkappaB kinase-activating kinase. Nature. 2000;404(6779):778–82.

42. Soutar D, et al. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 2008;27(15):2135–46.

43. Shu C, et al. Structural insights into the functions of TBK1 in innate antimicrobial immunity. Structure. 2013;21(7):137–48.

44. Ma X, et al. Molecular basis of tank-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad Sci U S A. 2012;109(24):9378–83.

45. Ikeda F, et al. Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in regulation of IFN-inducible genes. EMBO J. 2007;26(14):3451–62.

46. Li J, et al. Crystal structure of the ubiquitin-like domain of human TBK1. Protein Cell. 2012;3(5):383–91.

47. Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity. Science. 2007;26(13):1137–48.

48. Cold Spring Harb Perspect Biol. 2010;2(3):a000158.

49. Goncalves A, et al. Functional dissection of the TBK1 molecular network. PLoS One. 2011;6(9):e23971.

50. Fang R, et al. NEMO dependent and independent manner. PLoS Pathog. 2010;6(12):e100158.

51. Rehman R, et al. Acute TBK1/IKKe inhibition enhances the generation of disease-associated microglia-like phenotype upon cortical stab-wound injury. Front Aging Neurosci. 2021;13:684171.

52. Santos-Garcia D, et al. First case of Parkinsonian-pyramidal syndrome associated with a TBK1 mutation. Mov Disord. 2021;36(2):523–5.

53. Foster AD, et al. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Mol Cell Neurosci. 2020;108:103539.

54. Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631–6.
53. Chen KR, et al. TBK1-associated protein in endolysosomes (TAPE)/

56. Sparrer KMJ, et al. TRIM23 mediates virus-induced autophagy via activa-

59. Tang JL, et al. Histone deacetylase 3 promotes innate antiviral immunity

61. Friedman CS, et al. The tumour suppressor CYLD is a negative regulator

63. Gabhann JN, et al. Absence of SHIP-1 results in constitutive phosphory-

64. An H, et al. SHP-2 phosphatase negatively regulates the TRIF adaptor

65. Qi D, et al. Phosphatase Cdc25A negatively regulates the anti-

66. Zhan Z, et al. Phosphatase PP4 negatively regulates type I IFN produc-

68. Bodur C, et al. The IKK-related kinase TBK1 activates mTORC1 directly

69. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

70. Harris J, et al. Nuclear accumulation of cRel following C-terminal phos-

74. Lafont E, et al. TBK1 and IKKepsilon prevent TNF-induced cell death by

75. Lei CQ, et al. Glycogen synthase kinase 3beta regulates IRF3 transcrip-

76. Pourcelot M, et al. The Golgi apparatus acts as a platform for TBK1

77. Tu D, et al. Structure and ubiquitination-dependent activation of TANK-

78. Jin J, et al. The kinase TBK1 controls IgA class switching by nega-

79. Xie X, et al. IkappaB kinase epsilon and TANK-binding kinase 1

81. Hu L, et al. TBK1 is a synthetic lethal target in Cancer with VHL loss. Cancer Discovery. 2020;10(3):460–75.

82. Helgason E, Phung QT, Dueber EC. Recent insights into the complexity of

83. Zhang C, et al. Structural basis of STING binding with and phosphoryla-

84. Song G, et al. E3 ubiquitin ligase RNF128 promotes innate antiviral

85. Larabi A, et al. Crystal structure and mechanism of activation of TANK-

86. Fang R, et al. MAVs activates TBK1 and IKKepsilon through TRAFs in

87. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that

88. Saul VV, et al. SUMO modification of TBK1 at the adapter-binding

89. Xia Z, et al. NAC1 potentiates cellular antiviral signaling by bridging

90. Wang C, et al. The E3 ubiquitin ligase Nrdp1 'preferentially' pro-

91. Cui J, et al. NLRP4 negatively regulates type I interferon signaling by

92. Tapparel C, Maurice D, Roux L. The activity of Sendai virus genomic

93. Xu X, et al. Complete genome sequence of herpes simplex virus 1

94. Li S, et al. Mapping a dynamic innate immunity protein interac-

95. Tu D, et al. Structure and ubiquitination-dependent activation of TANK-

96. Marzahn MR, et al. Higher-order oligomerization promotes localization

97. Lis H, et al. E3 ubiquitin ligase RNF128 promotes innate antiviral

98. Li F, et al. Structural insights into the ubiquitin recognition by OPTN

99. Clark K, et al. Novel cross-talk within the IKK family controls innate

100. Zhu L, et al. TBKBP1 and TBK1 form a growth factor signalling axis

101. Li X, et al. The tyrosine kinase Src promotes phosphorylation of the

102. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

103. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

104. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

105. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

106. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

107. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

108. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

109. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

110. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

111. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

112. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

113. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

114. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

115. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

116. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

117. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

118. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

119. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

120. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

121. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

122. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

123. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in

124. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in
104. Parvatiyar K, Barber GN, Harhaj EW. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J Biol Chem. 2010;285(20):14999–5009.

105. Zhang M, et al. Regulation of IkappaB kinase-related kinases.

106. Liu S, et al. Lck/Hck/Fgr-mediated tyrosine phosphorylation negatively regulates TBK1 to restrain innate antiviral responses. Cell Host Microbe. 2017;21(6):754–68 e5.

107. Deng M, et al. TRAF3IP3 negatively regulates cytosolic RNA induced anti-viral signaling by promoting TBK1 K48 ubiquitination. Nat Commun. 2020;11(1):2193.

108. Lin M, et al. USP38 inhibits type I interferon signaling by editing TBK1 Ubiquitination through NLRP4 Signalosome. Mol Cell. 2016;64(2):267–81.

109. An T, et al. DYRK2 negatively regulates type I interferon induction by promoting TBK1 degradation via Ser527 phosphorylation. PLoS Pathog. 2015;11(9):e1005179.

110. Zhang M, et al. TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and antiviral response by promoting posttranslational degradation of TANK-binding kinase 1. J Exp Med. 2012;209(10):1703–11.

111. Zheng Q, et al. Siglec-1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27. Cell Res. 2015;25(2):1211–26.

112. Wang L, Li S, Dorf ME. NEMO binds ubiquitinated TANK-binding kinase 1 (TBK1) to regulate innate immune responses to RNA viruses. PLoS One. 2012;7(9):e43756.

113. Liu D, et al. SOCS3 drives proteasomal degradation of TBK1 and negatively regulates antiviral innate immunity. Mol Cell Biol. 2015;35(14):2400–13.

114. Aravamudhan A, et al. TBK1 regulates YAP/TAZ and fibroblastic fibroblast activation. Am J Physiol Lung Cell Mol Physiol. 2020;3(185(5)):LS82–63.

115. Zhang Q, et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat Cell Biol. 2017;19(4):362–74.

116. Ye JS, et al. Lysine 63-linked TANK-binding kinase 1 ubiquitination by mindbomb E3 ubiquitin protein ligase 2 is mediated by the mitochondrial antiviral signaling protein. J Virol. 2014;88(21):12765–76.

117. Yang Q, et al. Host HDAC4 regulates the antiviral response by inhibiting the phosphorylation of IRF3. J Mol Cell Biol. 2019;11(2):158–69.

118. Liu Q, et al. GSNOR facilitates antiviral innate immunity by restricting TBK1 cysteine S-nitrosation. Redox Biol. 2021;47:102172.

119. Clement JF, Meloche S, Servant MJ. The IKK-related kinases: from innate immune recognition and antiviral signaling through step-by-step conformational changes. Nucleic Acids Res. 2015;11(9):e1005179.

120. Huo H, et al. LGP2 plays a critical role in MDA5-mediated antiviral activation. Nat Commun. 2014;5:461.

121. Hu JY, et al. Dimethyl fumarate dampens IL-17-ACT1-TBK1 axis-mediated phosphorylation of Regnase-1 and suppresses IL-17-induced IL8-C expression. Biochem Biophys Res Commun. 2020;521(4):957–63.

122. Jiang X, et al. Identification of TBK1 complexes required for the phosphorylation of IRF3 and the production of interferon β. J Biol Chem. 2017;284(17):1163–73.

123. Jiang X, et al. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. J Mol Cell Biol. 2017;214(5):1493–507.

124. Chen W, et al. Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 7. J Biol Chem. 2005;280(11):9689–902.

125. Xiao Y, et al. The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J Exp Med. 2017;214(5):1493–507.

126. Chen H, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell. 2010;147(2):436–46.

127. Smith H, et al. The role of TBK1 and IKKe in the expression and activation of Pellino 1. Biochem J. 2011;434(3):537–48.
157. Nakhaei P, et al. IkappaB kinase epsilon-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis. J Virol. 2012;86(2):726–37.
158. Lork M, et al. Importance of validating antibodies and small compound inhibitors using genetic knockout studies—T cell receptor-induced CYLD phosphorylation by IKKepsilon/TBK1 as a case study. Front Cell Dev Biol. 2018;6:40.
159. Buss H, et al. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-kappaB at serine 536 is mediated by multiple protein kinases including IkappaB kinase (IKK)-alpha, IKK-beta, IKKepsilon), TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor I31-mediated interleukin-8 transcription. J Biol Chem. 2004;279(5):55633–43.
160. Fujita F, et al. Identification of NAPA1, a regulatory subunit of IkappaB kinase-related kinases that potentiates NF-kappaB signaling. Mol Cell. 2003;23(21):770–93.
161. Bonnard M, et al. Deficiency of T2K leads to apoptotic liver degeneration. J Exp Clin Cancer Res. 2018;37:59.
162. Qu F, et al. TRAF6-dependent Act1 phosphorylation by the IkappaB kinase-related kinases. J Biol Chem. 2012;287(19):15328–39.
163. Cai J, et al. USP7-TRIM27 axis negatively modulates antiviral type I IFN expression. J Virol. 2012;86(2):726–37.
164. Cooper JM, et al. TBK1 provides context-selective support of innate immune responses. J Exp Med. 2012(11):2539–50.
165. Liu S, et al. Phosphorylation of innate immune adaptor protein 1 mediates the formation of TANK-binding kinase 1 (TBK1) and promotes cytotoxic T lymphocyte-induced apoptosis. J Immunol. 2012;189(4):20119.
166. Nandakumar R, et al. Intracellular bacteria engage a STING-TBK1-IFN regulatory factor 3 (IRF3) signaling axis. Nat Immunol. 2018;19(9):579–93.
167. Marchlik E, et al. Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J Leukoc Biol. 2010;88(6):1171–80.
168. Rehman R, et al. Acute TBK1/IKK-epsilon inhibition enhances the generation of disease-associated microglia-like phenotype upon cortical stab-wound injury. Front Aging Neurosci. 2021;13:6684171.
169. Taft J, et al. Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell. 2021;184(17):4447–4463.e20.
170. Glick D, Barth S, MacLeod KD. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(3):1–12.
171. Zaffagnini G, Martens S. Mechanisms of Selective Autophagy. J Mol Biol. 2016;428(10):Pt A:1714–24.
172. Hansen M, Rubinszttein DC, Walker DW. Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol. 2018;19(9):579–93.
173. Dikic I, Bazar M, Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(9):349–64.
174. Seglen PO, Gordon PB, Holen I. Non-selective autophagy. Semin Cell Dev Biol. 1990;1(6):441–8.
175. Reggiori F, et al. Autophagy: more than a nonselective pathway. Int J Cell Biol. 2012;2012:219625.
176. Kirk K, Logan C, Walker DW. A diversity of selective autophagy receptors. J Cell Sci. 2019;126(2):268–85.
177. Fraser J, et al. Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling. EMBO Rep. 2018;20(10):e47734.
178. Dikic I, Bazar M. Autophagy: cellular and molecular mechanisms. J Mol Biol. 2016;428(10):pt a:1714–24.
179. Khaminets A, Behl C, Dikic I. Ubiquitin-dependent and independent selective autophagy of mitochondria on a ubiquitin-related platform. Autophagy. 2016;12(11):9119.
180. Zacharia M, et al. Selective autophagy of mitochondria on a ubiquitin-endoplasmic-reticulum platform. Dev Cell. 2020;55(2):251.
181. Ravenhill BJ, et al. The cargo receptor NDP52 initiates selective autophagy by recruiting theULK complex to cytosol-invasive Bacteria. Mol Cell. 2019;74(2):320–329 e6.
182. Shi X, et al.ULK complex organization in autophagy facilitates BCR recycling and signalling. EMBO Rep. 2018;19(10):e47734.
183. Dikic I, Bazar M. Autophagy: more than a nonselective pathway. Int J Cell Biol. 2012;2012:219625.
184. Khaminets A, Behl C, Dikic I. Ubiquitin-dependent and independent selective autophagy of mitochondria on a ubiquitin-related platform. Dev Cell. 2020;55(2):251.
185. Ravenhill BJ, et al. The cargo receptor NDP52 initiates selective autophagy by recruiting theULK complex to cytosol-invasive Bacteria. Mol Cell. 2019;74(2):320–329 e6.
186. Dikic I, Bazar M. Autophagy: more than a nonselective pathway. Int J Cell Biol. 2012;2012:219625.
209. Radtke AL, et al. TBK1 protects vacuolar integrity during intracellular bacterial infection. PLoS Pathog. 2007;3(3):e29.

210. Wu Y, et al. Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression. Autophagy. 2021;17(6):1579–92.

211. Zitouni S, et al. Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol. 2014;15(7):433–52.

212. Thornton BR, Toczyski DP. Precise destruction: an emerging picture of the APC. Genes Dev. 2006;20(22):3069–78.

213. Weil R, Laplantine E, Genin P. Regulation of TBK1 activity by Optineurin contributes to cell cycle-dependent expression of the interferon pathway. Cytokine Growth Factor Rev. 2016;29:23–33.

214. Gong KQ, Frevert C, Manicone AM. Deletion of LysM in LysMCre Recombinase homozygous mice is non-contributory in LPS-induced acute lung injury. Lung. 2019;197(6):819–23.

215. Gao T, et al. Myeloid cell TBK1 restricts inflammatory responses. Proc Natl Acad Sci U S A. 2022;119(4):ei210742119.

216. Duan W, et al. Myeloid TBK1 deficiency induces motor deficits and axon degeneration through inflammatory cell infiltration. Mol Neurobiol. 2021;58(5):2435–46.

217. Hagan RS, Torres-Castillo J, Doerschuk CM. Myeloid TBK1 signaling contributes to the immune response to influenza. Am J Respir Cell Mol Biol. 2019;60(3):335–45.

218. Xu J, et al. Inhibition of TBK1/IKKepsilon promotes regeneration of T-helper 17 cells and tumorigenesis in mice. Gastroenterology. 2020;201(5):1793–806.

219. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.

220. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011;30(6):631–41.

221. Jiang Y, et al. TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration. Front Immunol. 2021;12:612139.

222. Vu HL, Aplin AE. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant KRAS melanoma. Mol Cancer Res. 2014;12(10):1509–9.

223. Carr M, et al. IKKepsilon and TBK1 in diffuse large B-cell lymphoma: a new treatment for recurrent minor aphthous ulcers. I. clinical demonstration of acceleration of healing and resolution of pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83(2):222–30.

224. Liu Y, et al. Amlexanox, a selective inhibitor of IKKbeta, generates anti-tumour effects by disrupting the hippo pathway in human glioblastoma cell lines. Cell Death Dis. 2017;8(8):e3022.

225. Möller M, et al. The specific IKKepsilon/TBK1 inhibitor Amlexanox suppresses human melanoma by the inhibition of autophagy, NF-kB and MAP kinase pathways. Int J Mol Sci. 2020;21(13):4721.

226. Sun, Q, et al. TBK1/Ikkk inhibitor Amkl Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo. 2018: Blood.

227. Xiong J, et al. Amlexanox enhances Temozolomide-induced antitumor effects in human Glioblastoma cells by inhibiting IKKbeta and the Akt-mTOR signaling pathway. ACS Omega. 2021;6(6):4289–99.

228. Lefranc J, et al. Discovery of BA1-985, a highly selective TBK1/Ikkbeta inhibitor. J Med Chem. 2020;63(2):601–12.

229. Clark K, et al. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and Ikkappa kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2012;287(10):6457–63.

230. McVier EG, et al. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/Ikkk kinases. Bioorg Med Chem Lett. 2012;22(3):7169–73.

231. Feldman RI, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005;280(20):19867–74.

232. Hasan M, et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J Immunol. 2015;195(10):4573–7.

233. Perritor TR, et al. Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them. United States: Domainex Limited (GB). 2015.

234. Thomson DW, et al. Discovery of GSK8612, a highly selective and potent IKKepsilon and/or TBK1 inhibitor. ACS Med Chem Lett. 2019;10(5):780–5.

235. Muvaffak A, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer. 2018;7(8):1029–38.

236. Hsieh JJ, et al. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018;36(36):CO2018792549.

237. Kim JK, et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia. 2013;15(9):1064–74.

238. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.

239. Shigawara Y, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298–312.

240. Barbie DA, et al. Phase 1B study of Momelotinib combined with PHP110, a selectiveIKKepsilon inhibitor, in patients with myelofibrosis treated with or without ruxolitinib. Blood. 2018;131(17):1823–30.

241. Byrnes EA, et al. Phase 1B study of Momelotinib combined with Trametinib in metastatic, Kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung Cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer. 2018;19(6):e853–9.
263. Harrison CN, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–81.

264. Mesa RA, et al. SIMPLIFY-1: a phase III randomized trial of Momelotinib versus Ruxolitinib in Janus kinase inhibitor-naive patients with Myelofibrosis. J Clin Oncol. 2017;35(34):3844–50.

265. Ng K, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019;37(1):159–65.

266. Padda SK, et al. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2022;89(1):105–15.

267. Zheng J, et al. Pharmacokinetics and disposition of Momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018;46(3):237–47.

268. Richards B, et al. Cellular and in vivo properties of MPI-0485520, a novel and potent small molecule inhibitor of IKKe. FASEB J. 2010;24(S1):753.6–753.6.

269. Richters A, et al. Identification and further development of potent TBK1 inhibitors. ACS Chem Biol. 2015;10(1):289–98.

270. Li J, et al. Selective TBK1/IKKs dual inhibitors with antitumor potencies. Int J Cancer. 2014;134(8):1972–80.

271. Crew AP, et al. Identification and characterization of Von Hippel-Lindau recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J Med Chem. 2018;61(2):583–98.

272. Cheng C, et al. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKvarepsilon/TBK1/NF-kappaB signaling Theranostics. 2018;8(17):4633–48.

273. Gonzalez-Hilarion S, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012;7:58.

274. Tamai H, et al. Amlexanox Downregulates S100A6 to sensitize. Cancer Res. 2017;77(16):4426–33.

275. Chan E, et al. Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget. 2018;9(24):16599–618.

276. Challa S, et al. Targeting the IkappaB kinase enhancer and its feedback circuit in pancreatic Cancer. Transl Oncol. 2020;13(2):481–9.

277. Ramadas V, Vayapuri T, Tergaonkar V. Small molecule NF-κB pathway inhibitors in clinic. Int J Mol Sci. 2020;21(1):1564.

278. Thomas DW, Bergamini G. Recent progress in small molecule TBK1 inhibitors: a patent review (2015–2020). Expert Opin Ther Pat. 2021;31(9):785–94.

279. Cruz VH, Brekken RA. Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. J Cell Commun Signal. 2018;12(1):83–90.

280. Oral EA, et al. Inhibition of IKKvarepsilon and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab. 2017;26(1):157–170 e7.

281. Verstovsek S, et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021;17(12):1449–58.

282. Battle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34.

283. Vetrie D, Hélégson GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158–73.

284. Chen S, et al. TBK1-mediated DRP1 targeting confers nucleic acid sensing to reprogram mitochondrial dynamics and physiology. Mol Cell. 2020;80(5):810–827.e7.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.